[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 237
1. Kim KH, Sul HJ, Kang DY: Sclerosing hemangioma with lymph node metastasis. Yonsei Med J; 2003 Feb;44(1):150-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma with lymph node metastasis.
  • Sclerosing hemangioma (SH) of the lung is an uncommon type of tumor, which is composed of polygonal and cuboidal cells.
  • This disease is generally regarded as benign but extremely rare cases with lymph node metastasis have been reported.
  • We report a case of SH with a metastasis to the regional lymph nodes.
  • A 19-year-old girl presented with a 2-year history of coughing.
  • As a result, a left lower lobectomy with a dissection of the hilar and interlobar lymph nodes was performed.
  • Both types of tumor cells were uniformly immunoreactive to the epithelial membrane antigen (EMA) and the thyroid transcription factor-1 (TTF-1).
  • Postoperatively, the patient received chemotherapy and no recurrence or metastasis 2 years after surgery was noted.
  • Although a pulmonary SH is considered to be benign, this case highlights the need for the evaluation of lymph node metastasis.
  • [MeSH-major] Hemangioma / pathology. Lung Neoplasms / pathology. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619190.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer; 2009 Oct-Dec;46(4):274-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in adult soft tissue sarcoma.
  • Soft tissue sarcomas (STSs) are rare and histologically diverse neoplasms.
  • Recent results of various meta-analyses and development of newer drugs have changed the medical management of soft tissue sarcoma.
  • This review gives an outline of chemotherapy and the newer targeted therapies for the same.
  • We have carried out an extensive search in PubMed, Medline for almost all relevant articles concerning chemotherapy of soft tissue sarcoma.
  • The available data from the literature is mainly composed of the most recent reviews, meta-analyses, phase II, and randomized phase III trials published in various peer reviewed journals and various international conferences.
  • The role of neoadjuvant and adjuvant chemotherapy has been found to be controversial.
  • The recent meta-analysis for adjuvant therapy in STSs has shown an increase in the overall survival with combination of ifosfamide and adriamycin.
  • In locally advanced and metastatic STSs, single agent adriamycin remains the basic standard of medication.
  • Newer combinations of docetaxel and gemcitabine appear promising in selected subgroups, especially in leiomyosarcoma and malignant fibrous histiocytoma.
  • Some recent developments include the European Union's approval of trabectedin for advanced STSs patients who had progressed on adriamycin and ifosfamide therapy.
  • The future of mTOR inhibitors, insulin like growth factor receptor inhibitors and anti-angiogenic drugs appear quite promising.
  • Newer methodologies such as, Bayesian adaptive randomization and inclusion of newer end points like progression-free rate, time of progression rate, and tumor growth rate will improve the results of sarcoma trials.
  • At the end of each section we have also presented recommendations from FNx01European Society of Medical Oncology and FNx08National Comprehensive Cancer Network guidelines v.1.2009 for better correlation with the present literature.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoadjuvant Therapy


3. Hugate RR, Wilkins RM, Kelly CM, Madsen W, Hinshaw I, Camozzi AB: Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res; 2008 Jun;466(6):1292-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.
  • The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [3, 5, 6, 20, 22, 35].
  • We designed a neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous histiocytoma of bone in an attempt to improve survival.
  • We report the results of treating 53 adults (age 18-77 years) diagnosed with nonmetastatic extremity osteosarcoma or malignant fibrous histiocytoma.
  • Preoperative chemotherapy consisted of intravenous doxorubicin followed by intraarterial cisplatinum administered repetitively every 3 weeks for three to five cycles, depending on tumor response assessed by serial arteriography.
  • After resection, good responders (90% or greater necrosis) underwent treatment with the same agents and poor responders were treated with alternative agents for longer duration.
  • LEVEL OF EVIDENCE: Level III, therapeutic study.
  • See the Guidelines for Authors for a complete description of levels of evidence.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Neoplasms / drug therapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Histiocytoma, Malignant Fibrous / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arm Bones. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Leg Bones. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Ann Oncol. 1992 Apr;3 Suppl 2:S3-6 [1622860.001]
  • [Cites] Chir Organi Mov. 1996 Sep-Dec;81(4):369-82 [9147928.001]
  • [Cites] Clin Orthop Relat Res. 1997 Apr;(337):216-25 [9137193.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):765-71 [9332684.001]
  • [Cites] Acta Oncol. 1998;37(1):41-8 [9572653.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):423-31 [8113851.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jul;165(1):135-42 [7785572.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):631-7 [10203605.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:58-61 [10429624.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):949-56 [10491520.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10):1637-43 [10520703.001]
  • [Cites] Clin Orthop Relat Res. 2004 Dec;(429):286-91 [15577500.001]
  • [Cites] J Vasc Interv Radiol. 2005 Aug;16(8):1107-19 [16105923.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:128-36 [16131881.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8845-52 [16246977.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1154-61 [16421923.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):112-28 [17227995.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):118-23 [17577221.001]
  • [Cites] Tumori. 1999 Nov-Dec;85(6):458-64 [10774566.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):874-81 [11079583.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] J Chemother. 2001 Feb;13(1):93-9 [11233808.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1145-50 [11583198.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):498-507 [12794015.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):101-10 [5225072.001]
  • [Cites] JAMA. 1972 Sep 4;221(10):1132-8 [4512088.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):14-8 [299812.001]
  • [Cites] Med Pediatr Oncol. 1978;4(2):127-32 [275532.001]
  • [Cites] Cancer. 1979 Jun;43(6):2163-77 [88251.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):248-54 [6936069.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):1-4 [6263447.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):917-20 [6681533.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):402-7 [6571796.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1101-4 [3874932.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):194-202 [3164231.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):63-7 [2910425.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):839-42 [2916040.001]
  • [Cites] Skeletal Radiol. 1990;19(3):165-72 [2185556.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1703-10 [2208024.001]
  • [Cites] Clin Orthop Relat Res. 1991 Mar;(264):156-68 [1997230.001]
  • [Cites] Ann Oncol. 1991 Jul;2(7):489-94 [1911456.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):269-73 [1793151.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):411-5 [9010116.001]
  • (PMID = 18437502.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2384032
  •  go-up   go-down


Advertisement
4. Thompson JF, Siebert GA, Anissimov YG, Smithers BM, Doubrovsky A, Anderson CD, Roberts MS: Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer; 2001 Jul 20;85(2):157-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
  • This study sought to use a microdialysis technique to relate clinical and biochemical responses to the time course of melphalan concentrations in the subcutaneous interstitial space and in tumour tissue (melanoma, malignant fibrous histiocytoma, Merkel cell tumour and osteosarcoma) in patients undergoing regional chemotherapy by Isolated Limb Infusion (ILI).
  • 19 patients undergoing ILI for treatment of various limb malignancies were monitored for intra-operative melphalan concentrations in plasma and, using microdialysis, in subcutaneous and tumour tissues.
  • There was no significant difference between drug peak and mean concentrations in interstitial and tumour tissue, indicating that there was no preferential uptake of melphalan into the tumours.
  • The time course of melphalan in the microdialysate could be described by a pharmacokinetic model which assumed melphalan distributed from the plasma into the interstitial space.
  • Tumour response in the whole group to treatment was partial response: 53.8% (n = 7); complete response: 33.3% (n = 5); no response: 6.7% (n = 1).
  • There was a significant association between tumour response and melphalan concentrations measured over time in subcutaneous microdialysate (P< 0.01).
  • It is concluded that microdialysis is a technique well suited for measuring concentrations of cytotoxic drug during ILI.
  • The possibility of predicting actual concentrations of cytotoxic drug in the limb during ILI using our model opens an opportunity for improved drug dose calculation.
  • The combination of predicting tissue concentrations and monitoring in microdialysate of subcutaneous tissue could help optimise ILI with regard to post-operative limb morbidity and tumour response.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Melphalan / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Merkel Cell / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Humans. Melanoma / drug therapy. Microdialysis. Middle Aged. Osteosarcoma / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):47-54 [10711640.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10 [6891640.001]
  • [Cites] Am J Physiol. 1984 May;246(5 Pt 2):R665-77 [6720989.001]
  • [Cites] J Pharmacokinet Biopharm. 1988 Feb;16(1):41-83 [3373419.001]
  • [Cites] J Intern Med. 1991 Oct;230(4):365-73 [1919432.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1811-3 [1389515.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):151-3 [8018528.001]
  • [Cites] J Pathol. 1995 Jul;176(3):279-87 [7674090.001]
  • [Cites] Melanoma Res. 1995 Dec;5(6):425-31 [8589617.001]
  • [Cites] Cancer Lett. 1996 Feb 6;99(2):225-31 [8616828.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):920-4 [8611407.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 Nov 17;673(2):267-79 [8611961.001]
  • [Cites] Br J Surg. 1996 Oct;83(10):1319-28 [8944445.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):267-72 [8996531.001]
  • [Cites] Melanoma Res. 1997 Feb;7(1):19-26 [9067961.001]
  • [Cites] Melanoma Res. 1997 Jun;7(3):252-64 [9195565.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2598-601 [9205062.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):903-7 [9267277.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):238-47 [9548607.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2982-5 [9679959.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2906-12 [9738557.001]
  • [Cites] Electrophoresis. 1998 Nov;19(16-17):2981-5 [9870399.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):522-30 [10235581.001]
  • [Cites] Ann Pharmacother. 1999 Jun;33(6):730-8 [10410188.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1000-3 [10737379.001]
  • (PMID = 11461070.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2364039
  •  go-up   go-down


5. Padula GD, Schmitz M: Adult paratesticular malignant fibrous histiocytoma treated with surgery, systemic chemotherapy and postoperative adjuvant radiotherapy. J Cancer Res Ther; 2006 Oct-Dec;2(4):201-2
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult paratesticular malignant fibrous histiocytoma treated with surgery, systemic chemotherapy and postoperative adjuvant radiotherapy.
  • Paratesticular malignant fibrous histiocytoma is an extremely rare malignancy of the scrotum.
  • We present here a case of a 57-year-old man with a diagnosis of high-grade malignant fibrous histiocytoma of the left intrascrotal region who underwent radical orchiectomy, systemic chemotherapy and postoperative radiotherapy.
  • [MeSH-major] Genital Neoplasms, Male / therapy. Histiocytoma, Malignant Fibrous / therapy. Scrotum / radiation effects
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryptorchidism / complications. Erythema / etiology. Humans. Lipomatosis / complications. Male. Middle Aged. Orchiectomy. Radiotherapy, Adjuvant / adverse effects. Tinea / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998705.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, Libermann TA, Gebhardt MC, Spentzos D: Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One; 2010;5(4):e9747
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.
  • BACKGROUND: Diagnosis of soft tissue sarcomas (STS) is challenging.
  • Many remain unclassified (not-otherwise-specified, NOS) or grouped in controversial categories such as malignant fibrous histiocytoma (MFH), with unclear therapeutic value.
  • We analyzed several independent microarray datasets, to identify a predictor, use it to classify unclassifiable sarcomas, and assess oncogenic pathway activation and chemotherapy response.
  • We developed and validated a predictor, which was used to reclassify MFH and NOS sarcomas.
  • Bayesian models of oncogenic pathway activation and chemotherapy response were applied to individual STS samples.
  • A 170-gene predictor was developed and independently validated (80-85% accuracy in all datasets).
  • Most MFH and NOS tumors were reclassified as leiomyosarcomas, liposarcomas and fibrosarcomas.
  • This classification revealed previously unrecognized tissue differentiation lines (adipocyte, fibroblastic, smooth-muscle) and was reproduced in paraffin specimens.
  • CONCLUSIONS/SIGNIFICANCE: STS profiling can aid in diagnosis through a predictor tracking distinct tissue differentiation in unclassified tumors, and in therapeutic management via oncogenic pathway activation and chemotherapy response assessment.
  • [MeSH-major] Bayes Theorem. Neural Networks (Computer). Oligonucleotide Array Sequence Analysis. Sarcoma / classification. Sarcoma / genetics
  • [MeSH-minor] Cluster Analysis. Databases, Nucleic Acid. Drug Resistance, Neoplasm / genetics. Expert Systems. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. Soft Tissue Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2001;3(2):77-80 [11250749.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Curr Oncol Rep. 2001 May;3(3):243-9 [11296135.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):330-9 [18286476.001]
  • [Cites] Methods Mol Biol. 2008;439:159-77 [18370102.001]
  • [Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]
  • [Cites] Expert Opin Ther Targets. 2008 May;12(5):589-603 [18410242.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):543-8 [14962721.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Cancer Treat Res. 2004;120:151-67 [15217223.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1799-807 [15509548.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):349-59 [3566372.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:318-26 [9474886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5881-9 [15994966.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6280-90 [16144932.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7332-41 [16145063.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Biostatistics. 2007 Jan;8(1):118-27 [16632515.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):517-25 [17290060.001]
  • [Cites] Clin Transl Oncol. 2007 Mar;9(3):130-44 [17403624.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] PLoS One. 2007;2(10):e1002 [17912341.001]
  • [Cites] PLoS One. 2007;2(11):e1195 [18030330.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):346-51 [18199526.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):1-9 [18187804.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • (PMID = 20368975.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2848563
  •  go-up   go-down


8. Miyagawa-Hayashino A, Tazelaar HD, Langel DJ, Colby TV: Pulmonary sclerosing hemangioma with lymph node metastases: report of 4 cases. Arch Pathol Lab Med; 2003 Mar;127(3):321-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary sclerosing hemangioma with lymph node metastases: report of 4 cases.
  • CONTEXT: Sclerosing hemangioma is an unusual pulmonary tumor.
  • Previously, 4 patients with pulmonary sclerosing hemangioma and lymph node metastases have been described in the literature.
  • OBJECTIVE: To report 4 additional cases of metastatic sclerosing hemangioma.
  • RESULTS: Four cases of a morphologically benign pulmonary sclerosing hemangioma with regional lymph node metastases (including hilar, peribronchial, and interlobar metastases) were identified.
  • The pulmonary tumors were typical circumscribed sclerosing hemangiomas without mitotic activity, angiolymphatic invasion, or necrosis.
  • One patient received adjuvant chemotherapy for adenocarcinoma.
  • CONCLUSIONS: On the basis of case data from the 4 patients described here and the 4 patients described previously, metastases to regional lymph nodes from pulmonary sclerosing hemangioma may occur but are rare and do not appear to affect prognosis.
  • [MeSH-major] Hemangioma / diagnosis. Lung Neoplasms / diagnosis. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12653576.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Goto T, Kosaku H, Kobayashi H, Hozumi T, Kondo T: [Soft tissue sarcoma: postoperative chemotherapy]. Gan To Kagaku Ryoho; 2004 Sep;31(9):1324-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma: postoperative chemotherapy].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • The efficacy of chemotherapy varies according to the histological type of sarcoma.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy.
  • On the other hand, the efficacy of chemotherapy is not statistically demonstrated in non-round cell sarcomas, e. g., malignant fibrous histiocytoma.
  • Nowadays, several kinds of antitumor agents are usually used for adjuvant chemotherapy, and many authors have reported various kinds of regimens and their clinical results.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate, cyclophosphamide, dacarbazine, vincristine, and actinomycin-D.
  • Recently, high-dose chemotherapy combined with autologous peripheral blood or bone marrow stem cell transplantation has been begun in patients who do not respond to standard chemotherapy, and a better prognosis is expected.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Melphalan / administration & dosage. Mesna / administration & dosage. Methotrexate / administration & dosage. Osteosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15446551.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; MAID protocol; VAIA protocol
  • [Number-of-references] 76
  •  go-up   go-down


10. Yamamura R, Yamane T, Aoyama Y, Nakamae H, Makita K, Shima E, Ohta K, Inoue T, Sakamoto H, Hino M: Development of chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma. Acta Haematol; 2003;109(3):141-4
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma.
  • At the age of 28, a 33-year-old male was diagnosed with malignant fibrous histiocytoma (MFH) with a primary lesion in the right maxillary sinus.
  • Although arterial infusion chemotherapy (pirarubicin hydrochloride and carboplatin) was given, no tumor shrinkage was observed, and surgery was therefore performed to remove the tumor.
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment.
  • The clinical course of this patient strongly suggests that this was a case of treatment-related CML that developed after chemotherapy for MFH.
  • Treatment-related malignant blood diseases are known to include acute myelocytic leukemia and myelodysplastic syndrome, but reports of treatment-related CML are rare, although there have been some cases of treatment-related CML occurring several years after pretreatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Histiocytoma, Benign Fibrous / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Maxillary Sinus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12714824.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Hoshi M, Takami M, Ieguchi M: Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. Radiat Med; 2008 Oct;26(8):499-503
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
  • We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously.
  • Although these metastases responded well to systemic chemotherapy, brain metastases newly appeared and caused the death of the patient.
  • These findings demonstrate that individual sarcomatous metastatic organs exhibit different sensitivities to chemotherapy.
  • The mechanism of this phenomenon is discussed with a review of previous reports.
  • It is suggested that the blood-brain barrier may play an important role in sensitivity to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Brain Neoplasms / drug therapy. Histiocytoma, Malignant Fibrous / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Acetabulum. Bone and Bones / drug effects. Brain / drug effects. Doxorubicin / administration & dosage. Forearm. Humans. Ifosfamide / administration & dosage. Lung / drug effects. Male. Middle Aged


12. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Maeura Y, Ueda N, Matsunaga S, Ohta H, Okamoto S: [A case of malignant fibrous histiocytoma of mesocolon successfully resected after combined chemotherapy with epirubicin, CDDP and vincristine]. Gan To Kagaku Ryoho; 2000 Feb;27(2):299-302
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant fibrous histiocytoma of mesocolon successfully resected after combined chemotherapy with epirubicin, CDDP and vincristine].
  • We experienced a case of MFH of the sigmoid mesocolon which was successfully resected after preoperative combined chemotherapy.
  • The tumor had extensively invaded the surrounding tissue and an incisional biopsy was done.
  • Ten cycles of post-operative chemotherapy with doxorubicin were effective for a complete remission.
  • Three cycles of combined chemotherapy with epirubicin, CDDP and vincristine led to a regression of the tumor and no distant metastasis was found.
  • The tumor was successfully resected with a negative surgical margin.
  • The patient has been in good health for 7 years and 2 months after the second operation without further therapy.
  • In cases of MFH such as the present in which the patient is sensitive to chemotherapy, neoadjuvant chemotherapy might be effective in allowing minimal surgery and offering a better quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / surgery. Mesocolon. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Epirubicin / administration & dosage. Humans. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700905.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Chugh R, Thomas D, Wathen K, Thall PF, Benjamin RS, Maki RS, Samuels BL, Keohan ML, Priebat DA, Baker LH: Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):9001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial.
  • METHODS: Patients ≥10 years old with a sarcoma subtype not curable by multidisciplinary management were eligible.
  • Rules for early termination within each disease type were based on a hierarchical Bayesian probability model accounting for correlation of the responses of the 10 disease types.
  • Tissue specimens were analyzed by immunohistochemistry for c-kit, PDGFRα, PDGFR****223'3f NEEDS TO BE ADDED TO TIMES NEW ROMAN GREEK FONT****, AKT, PTEN, FKHR, and by allelic PCR analysis for PDGFRα exon 18.
  • Patients received prior chemotherapy and all had progressive disease.
  • Four month progression-free survival (PFS) rates follow: all sarcoma subtypes 18% (27/147), angiosarcoma 10% (1/10), Ewing sarcoma 0% (0/13), fibrosarcoma 29% (2/7), liposarcoma 32% (9/28), leiomyosarcoma (LMS) 20% (6/30), malignant fibrous histiocytoma 1/15 (7%), osteosarcoma 18% (3/17), peripheral nerve sheath tumor 20% (1/5), rhabdomyosarcoma 0% (0/2), synovial sarcoma 20% (4/20).
  • CONCLUSIONS: Further investigation of imatinib in the therapy of liposarcoma, LMS, and fibrosarcoma is warranted.
  • The hierarchical Bayesian probability model is an effective method for studying rare diseases and their subtypes, when it is reasonable to assume that their response rates are exchangeable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis and treatment is unclear.
  • We analysed diseases outcomes (disease free survival, DFS) by histology high risk factors (tumor size, histology, and proliferation index).
  • Heterogeneous chemotherapy/radiotherapy schedules was evaluated .
  • RESULTS: Seven cases of PBS (1 male/6 female) were reviewed, from 790 BC diagnosed (0.8%): 2 angiosarcomas (AS), 1 malignant fibrous histiocytoma, 2 undifferentiated, one osteoclastic and other spindle-cell sarcoma.
  • Adjuvant therapy was radiation 57.14% pts; and chemotherapy (doxorubicin 4/liposomal doxorubicin 2 pts) in recurrence.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Deckert PM, Siehl JM, Thiel E, Schmittel A, Hütter G, Szelényi H, Keilholz U: Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):9011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma.
  • : 9011 Background: Anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma.
  • METHODS: In a single-arm phase II study 40 patients were enrolled with a median age of 57 years (19 to 78 years).
  • Treatment regimen was L-Dauno 100 mg/m2 and ifosfamide 5 g/m2 over 24 h every 4 weeks with G-CSF support.
  • Initially, 5 patients were included after failure of a doxorubicin/ifosfamide regimen, but none of these responded.
  • Treatment had to be terminated due to a pseudo-allergic reaction to L-Dauno in one patient.
  • One patient had ifosfamide related acute renal failure and was further treated with L-Dauno alone.
  • Eleven (31,4 %) out of 35 patients without pretreatment achieved a PR, all after 2 treatment cycles, 6 patients (17,1 %) had stable disease and 12 patients (34,3 %) progressed; 6 patient were not evaluable (2 treatment unrelated early deaths, 2 lost to follow up, 1 adjuvant treatment, 1 to early to evaluate).
  • Median time to progression was 10 months, median overall survival 16 months.
  • PR with respect to histology was: 4/7 PNET, 1/6 leiomyosarcoma, 2/4 liposarcoma, 1/2 synovial sarcoma, 1/3 pleomorphic sarcoma, 1/1 malignant histiocytoma and 1/2 carcinosarcoma.
  • Four of the responding patients received a consolidating high-dose-chemotherapy with subsequent stem cell support.
  • CONCLUSIONS: IDx is a well tolerated and highly active chemotherapy regimen for first line treatment of soft tissue sarcoma, even in elderly patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013680.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kasper B, Ouali M, Van Glabbeke M, Blay J, Bramwell VH, Woll PJ, Schöffski P: Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):10573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials.
  • METHODS: Patients selected for analysis were treated in two randomized trials of adjuvant chemotherapy in STS (EORTC 62771 and 62931).
  • A total of 793 patients were included with a median follow-up (FU) of 8.74 years (AYA population: n = 161, median FU 9.46 years; patients ≥ 30 years: n = 632, median FU 8.62 years).
  • The variables of the multivariate analysis were gender, subtype and grade, tumor size and localization (limb vs. other), absence or presence of local recurrence and treatment (control arm vs. adjuvant chemotherapy).
  • RESULTS: Patients' characteristics were globally similar with two exceptions, histological subtype (p = 0.0043) and tumor size (p < .0001).
  • The commonest sarcoma subtype in the AYA population was synovial sarcoma (29 %), whereas leiomyosarcoma (18 %), malignant fibrous histiocytoma (MFH, 16 %) and liposarcoma (15 %) were more frequent in patients ≥ 30 years.
  • For OS, independent favorable prognostic factors were low grade and small tumor size for both groups; radical resection and MFH or liposarcoma subtype were factors of favorable prognosis for patients ≥ 30 years only.
  • For RFS, favorable prognostic factors were small tumor size and low grade for both groups; tumor location in the extremities was a factor of favorable prognosis for the AYA population only, whereas radical resection and adjuvant chemotherapy treatment were favorable factors for patients ≥ 30 years only.
  • Interestingly, adjuvant chemotherapy was associated with improved RFS only in patients ≥ 30 years.
  • The results may have further implications on the treatment of STS patients in different age groups as well as the design of future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Machak GN, Polotskiĭ BE, Meluzova OM, Chernov IS, Aliev MD: [Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin]. Vopr Onkol; 2010;56(2):220-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
  • Our investigation involved 27 patients with osteosarcoma and 2--malignant fibrous histiocytoma of long tubular bones treated at the Center's Clinics (2001-2008).
  • Surgical treatment used atypical resection of the lung or precision excision of metastasis.
  • Metastases were removed after a course of chemotherapy in 16 cases.
  • Hence, timely combination therapy of relapsed high-grade osteosarcoma may secure relatively long remission in 35-40.3%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Histiocytoma, Malignant Fibrous / drug therapy. Neoplasm Recurrence, Local / surgery. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552902.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Kusuzaki K, Shinjo H, Murata H, Takeshita H, Hashiguchi S, Nozaki T, Emoto K, Ashihara T, Hirasawa Y: Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities. Anticancer Res; 2000 Sep-Oct;20(5C):3813-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities.
  • We performed the present study to clarify the relationship between the DOX binding ability (%DB) and the histologic response, rate of decrease in tumor volume of malignant soft tissue tumors after preoperative chemotherapy and prognosis.
  • Nine malignant soft tissue tumors (4 liposarcomas, 3 synovial sarcomas, one malignant fibrous histiocytoma (MFH) and one extraskeletal osteosarcoma (EOS)) which arose at the extremities of adult patients were analyzed by the DOX binding assay using freshly biopsied specimens.
  • After preoperative chemotherapy including DOX or pirarubicin (THP), the rate of decrease in tumor volume was measured using magnetic resonance imaging, and the histologic response expressed as tumor necrosis to chemotherapy was also investigated.
  • All the patients, apart for one, were continuously disease-free after treatment.
  • These results suggest that in malignant soft tissue tumors, the rate of decrease in tumor volume after chemotherapy might be a better indicator for chemosensitivity than the histologic response and also that the DOX binding ability might be a good predictor for chemosensitivity before chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / pharmacokinetics. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Arm. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / pathology. Thigh

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268459.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin
  •  go-up   go-down


20. Yamauchi T, Misaki H, Arai H, Iwasaki H, Naiki H, Ueda T: An autopsy case of disseminated mucormycosis in a neutropenic patient receiving chemotherapy for the underlying solid malignancy. J Infect Chemother; 2002 Mar;8(1):103-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An autopsy case of disseminated mucormycosis in a neutropenic patient receiving chemotherapy for the underlying solid malignancy.
  • Here, we describe an autopsy case of disseminated mucormycosis in a neutropenic patient who was receiving chemotherapy for an underlying solid malignancy.
  • A 31-year-old Japanese man received cytotoxic chemotherapy with etoposide for the pulmonary metastasis of a secondary malignant fibrous histiocytoma.
  • This patient had long been treated with chemotherapeutic agents for this solid cancer and for the preceding eosinophilic granuloma, both of which were highly resistant to the therapy.
  • During the treatment with etoposide, his neutrophil count declined to less than 100/microl.
  • The chemotherapy was discontinued, and granulocyte colony-stimulating factor was administered.
  • The therapy-related severe neutropenia, and the probable impairment of the immune system, because of the previous chemotherapies, would have been responsible for this fatal infection.
  • [MeSH-major] Histiocytoma, Benign Fibrous / drug therapy. Mucormycosis / etiology. Neutropenia / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11957129.001).
  • [ISSN] 1341-321X
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Mandal S, Mandal AK: Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma. Int J Clin Oncol; 2007 Feb;12(1):52-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma.
  • Malignant fibrous histiocytoma (MFH) originates from primitive mesenchymal cells and has the capacity for dual differentiation into histiocytes and fibroblasts.
  • MFH occurring as a secondary malignancy following radio-chemotherapy is rare and its exact incidence is not yet known.
  • Here we report a case of a 42-year-old man who developed MFH in his right knee over a period of more than 10 years after radio (44 Gy)-chemotherapy to treat Hodgkin's lymphoma.
  • [MeSH-major] Bone Neoplasms / etiology. Histiocytoma, Malignant Fibrous / etiology. Hodgkin Disease / therapy. Muscle Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Dacarbazine / adverse effects. Doxorubicin / adverse effects. Humans. Male. Mechlorethamine / adverse effects. Neoplasms, Radiation-Induced / etiology. Prednisone / adverse effects. Procarbazine / adverse effects. Radiotherapy, Adjuvant. Vinblastine / adverse effects. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003187 [16235316.001]
  • [Cites] J Laryngol Otol. 2003 Mar;117(3):224-6 [12648384.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):859-63 [15581174.001]
  • [Cites] Clin Radiol. 2001 Jan;56(1):22-9 [11162693.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1630-47 [16356126.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):622-4 [15762368.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):371-4 [11888478.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2004;23(2):145-51 [15163293.001]
  • (PMID = 17380442.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


22. Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, Pringle J, Uscinska BM, Weeden S, Kirkpatrick A, Glabbeke Mv, Craft AW, European Osteosarcoma Intergroup: Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer; 2005 Jan;41(2):225-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
  • There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant fibrous histiocytoma (MFH-B).
  • Chemotherapy consisted of doxorubicin and cisplatin every 3 weeks for six cycles.
  • Median time to progression was 30 months (95% Confidence Interval (CI), 8-51 months) for the operable non-metastatic patients; median survival 41 months (95% CI, 16-82 months).
  • Median time to progression in the metastatic group was 10 months (95% CI, 0-18 months) and median survival was 14 months (95% CI, 4-45 months).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Rare Diseases / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Infusions, Intravenous. Lymphatic Metastasis. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome


23. Kozuka T, Kiura K, Katayama H, Fujii N, Ishimaru F, Ikeda K, Ueoka H, Hamasaki S, Yoshino T, Kashihara Y, Date H, Tanimoto M, Harada M: Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. Anticancer Res; 2002 Sep-Oct;22(5):2939-44
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.
  • BACKGROUND: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series.
  • The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established.
  • One patient with malignant fibrous histiocytoma recurred with multiple lung metastases.
  • This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin.
  • During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / therapy. Humans. Ifosfamide / administration & dosage. Male. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12530021.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


24. Shioya T, Yuzuriha R, Maejima K, Mizutani S, Nambu K, Hoshino A, Shibuya T, Tokunaga A, Matsumoto K, Tajiri T: Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy. Clin J Gastroenterol; 2008 Oct;1(3):122-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy.
  • Malignant fibrous histiocytoma of the liver is an extremely rare tumor.
  • Histopathologically, the tumor was diagnosed as a primary storiform-pleomorphic-type malignant fibrous histiocytoma of the liver.
  • One year after the radical operation, the patient developed recurrences in other organs.
  • She received 17 cycles of chemotherapy with etoposide, ifosfamide, and cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1992 Sep;21(3):290-2 [1328016.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):620-3 [17085355.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):386-91 [10390563.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W481-9 [17056878.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1331-9 [15446552.001]
  • (PMID = 26193650.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemotherapy / Liver / Malignant fibrous histiocytoma / Sarcoma / Surgery
  •  go-up   go-down


25. Bölke E, Ruf L, Budach W, Reinecke P, Röhrborn A, Pape H, Schwarz A, Schmitt G, Aul C: Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma. Wien Klin Wochenschr; 2005 Dec;117(23-24):833-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma created from fibroblast cells and characterized by a high rate of metastasis or recurrence with poor prognosis.
  • There was a high local recurrence and metastasis rate, and the patient was treated with radiotherapy and conventional chemotherapy followed by tandem high-dose chemotherapy and peripheral blood stem-cell transplantation.
  • We review the clinical picture of the tumor in this patient and discuss its diagnosis, pathogenesis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Thoracic Surgery. Transplantation, Autologous. Treatment Outcome


26. Kocer B, Gulbahar G, Erdogan B, Budakoglu B, Erekul S, Dural K, Sakinci U: A case of radiation-induced sternal malignant fibrous histiocytoma treated with neoadjuvant chemotherapy and surgical resection. World J Surg Oncol; 2008;6:138
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of radiation-induced sternal malignant fibrous histiocytoma treated with neoadjuvant chemotherapy and surgical resection.
  • BACKGROUND: Primary sternal malignant fibrous histiyocytoma (MFH) is highly rare.
  • Effective treatment modality is surgical resection with wide margins.
  • However, to date, the effects of radiotherapy or chemotherapy has not been clearly defined.
  • CASE PRESENTATION: Herein, we aimed to present a 50-year old female patient with MFH occurred in the radiotherapy field who had had surgical procedure for breast cancer 19 years ago and had followed by radiotherapy.
  • Neoadjuvant chemotherapy was applied for MFH due to cardiac and mediastinal vascular invasion.
  • Wide resection was carried out for the mass after having been decreased in size following neoadjuvant chemotherapy.
  • CONCLUSION: Neoadjuvant chemotherapy was an effective method.
  • In planning the surgical resection, the size of the tumor before chemotherapy should be considered as the initial size and surgical margins should be determined accordingly.
  • [MeSH-major] Bone Neoplasms / therapy. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy / adverse effects. Sternum / radiation effects
  • [MeSH-minor] Breast Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Jan 1;45(1):167-78 [6243239.001]
  • [Cites] Surg Clin North Am. 1980 Aug;60(4):779-91 [6999648.001]
  • [Cites] Diagn Interv Radiol. 2005 Mar;11(1):23-7 [15795839.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Sep;90(3):367-72 [4033174.001]
  • [Cites] Ann Thorac Surg. 1986 Jun;41(6):597-601 [3013106.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jan;111(1):96-105; discussion 105-6 [8551793.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):371-4 [11888478.001]
  • [Cites] J Thorac Cardiovasc Surg. 1986 Feb;91(2):234-7 [3003463.001]
  • (PMID = 19116008.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2628670
  •  go-up   go-down


27. Guillou L, Gebhard S, Salmeron M, Coindre JM: Metastasizing fibrous histiocytoma of the skin: a clinicopathologic and immunohistochemical analysis of three cases. Mod Pathol; 2000 Jun;13(6):654-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing fibrous histiocytoma of the skin: a clinicopathologic and immunohistochemical analysis of three cases.
  • The clinicopathologic and immunohistochemical features of three metastasizing fibrous histiocytomas of the skin are presented.
  • The second patient, who had a 3-cm nodule excised from his left thigh and inguinal lymph node metastasis after 4 months, had a favorable outcome 14 years after local radiotherapy and chemotherapy.
  • All three primary skin tumors involved the dermis and subcutis, appeared well-delineated but nonencapsulated, were associated with some degree of epidermal hyperplasia, and showed features of aneurysmal/atypical or cellular fibrous histiocytoma.
  • Recurrences and metastases showed morphologic features similar to primary lesions.
  • Cellular, aneurysmal, and atypical (pseudosarcomatous) fibrous histiocytomas of the skin can metastasize, yet they often show a protracted clinical course.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mod Pathol. 2001 May;14(5):534-6 [11353067.001]
  • (PMID = 10874670.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


28. Eguíluz Lumbreras P, Palacios Hernández A, Heredero Zorzo O, García García J, Cañada de Arriba F, Pérez Herrero F, Gómez Zancajo R: Retroperitoneal malignant fibrous histiocytoma: case report. Arch Esp Urol; 2010 Jul-Aug;63(6):477-9
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal malignant fibrous histiocytoma: case report.
  • OBJECTIVE: We present the case of a big retroperitoneal tumor that received the pathologic diagnosis of malignant fibrous histiocytoma.
  • We also review the diagnostic and therapeutic features of this disease in the current literature.
  • METHODS: We present the case of a 75-year-old male who was admitted to the Gastrointestinal Disease Department with asthenia of several months of evolution and gastrointestinal problems.
  • Pathology reportes malignant fibrous histiocytoma of the storiform-pleomorphic type, with hyaline degeneration foci (stadium pT2B).
  • They can adopt several different morphologic patterns, as well as many differentiation degrees.
  • The surgical treatment is still the only therapy with healing possibilities.
  • Adjuvant treatments through radiotherapy and/or chemotherapy are brought into question.
  • [MeSH-major] Histiocytoma, Malignant Fibrous. Retroperitoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20820088.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Fritz MA, Sade B, Bauer TW, Wood BG, Lee JH: Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension. Acta Neurochir (Wien); 2006 Jan;148(1):73-6; discussion 76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibrous histiocytoma of the pterygopalatine fossa with intracranial extension.
  • A very rare case of fibrous histiocytoma arising in the pterygopalatine fossa with intracranial extension is described.
  • The aggressive nature of our patient's tumor confirms previous observations that an aggressive radiographic appearance has prognostic value when dealing with skeletal and soft tissue tumors.
  • The benefit of multimodal therapy has not been established in these rare head and neck lesions.
  • In the subset of fibrous histiocytomas that invade bone, however adjunctive treatment with radiation and or chemotherapy may be appropriate.
  • [MeSH-major] Brain / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasm Recurrence, Local / pathology. Palate, Hard. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200478.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


30. Dilek TU, Dilek S, Pata O, Tataroglu C, Tok E: Malignant fibrous histiocytoma of the ovary: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:352-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the ovary: a case report.
  • Malignant fibrous histiocytoma is the most common type of soft tissue sarcoma in adults.
  • Primary malignant fibrous histiocytoma of the ovary is extremely rare, with only three previously reported cases.
  • We reported a rare and uncommon localization of malignant fibrous histiocytoma in a 22-year-old woman.
  • She was referred for adjuvant chemotherapy to our center with the diagnosis of storiform-pleomorphic malignant fibrous histiocytoma.
  • A left adnexal mass was detected by computed tomography of the lower abdomen.
  • Histopathologic examination revealed inflammatory, malignant fibrous histiocytoma.
  • The management of malignant fibrous histiocytoma is controversial because of the heterogenous nature of the disease.
  • Resection of all macroscopic disease is independently associated with improved disease-specific survival, and adjuvant chemotherapy for nonmyxoid variants could be acceptable alternatives if the surgical margins are tumor free.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Humans. Reoperation

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515621.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Kariya S, Aoji K, Kuyama K, Akagi H, Fukazawa M, Nishizaki K: Malignant fibrous histiocytoma of the parotid gland. Auris Nasus Larynx; 2003 Aug;30(3):315-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the parotid gland.
  • Primary malignant fibrous histiocytoma (MFH) arising in a major salivary gland is rare.
  • The patient was a 54-year-old man diagnosed as having pleomorphic type of MFH after extended total parotidectomy.
  • Accordingly treatment consisted in the resection of MFH and radiotherapy in combination with chemotherapy using carboplatin (CBDCA).
  • This postoperative therapy was effective in controlling the growth of the remaining tumor tissue.
  • As the patient showed no signs of local recurrence and distant metastasis for 5 years, plastic surgery was performed to improve the serious deformation of the face with a free anterolateral thigh flap.
  • [MeSH-major] Histiocytoma, Benign Fibrous. Parotid Gland. Salivary Gland Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927301.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


32. Kwinter J, DeKoven J: Generalized eruptive histiocytoma treated with isotretinoin. J Cutan Med Surg; 2009 May-Jun;13(3):146-50
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized eruptive histiocytoma treated with isotretinoin.
  • BACKGROUND: Generalized eruptive histiocytoma (GEH) is a rare, benign non-Langerhans cell histiocytosis characterized by widespread and symmetric skin-colored to blue-red papules on the trunk and proximal extremities affecting mainly adults.
  • GEH is associated with a self-limiting course lasting from 1 month to over 12 years, and the lesions typically resolve spontaneously; therefore, reports of potential therapies for GEH are lacking.
  • OBJECTIVE: We report for the first time the use of isotretinoin in the treatment of GEH.
  • An otherwise healthy 53-year-old female with a 3-month history of GEH had resolution of lesions without further development of new lesions over 8 months of treatment with isotretinoin, although, eventually, lesions began to recur.
  • [MeSH-major] Dermatologic Agents / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Isotretinoin / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Histiocytes / pathology. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19426623.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; EH28UP18IF / Isotretinoin
  •  go-up   go-down


33. Fukushima A, Yaegashi Y, Utsugisawa Y, Matsuta M, Kagabu T, Sugai T, Nakamura S: Malignant fibrous histiocytoma of the vagina. Int J Clin Oncol; 2001 Jun;6(3):153-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the vagina.
  • We describe here the case of an 82-year-old woman presenting with a hemorrhagic tumor on the anterior vaginal wall.
  • She was diagnosed with malignant fibrous histiocytoma (MFH) from the findings of cytological analysis of biopsied surface tissue, histopathologic analysis of biopsied tissue, immunohistochemical staining, and electron microscopy.
  • Electron microscopy showed histiocyte-derived cells with a segmented nucleus with a large groove, pseudopodic cytoplasmic projections, and lysosome-like structures.
  • Because of the patient's advanced age, and, in accordance with her wishes, three courses of cancer chemotherapy, consisting of doxorubicin hydrochloride, fluorouracil, and cisplatin were carried out, without surgery.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunohistochemistry. Microscopy, Electron

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11706786.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Misaki H, Yamauchi T, Arai H, Yamamoto S, Sutoh H, Yoshida A, Tsutani H, Eguchi M, Nagoshi H, Naiki H, Baba H, Ueda T, Yamakawa M: Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis. J Clin Exp Hematop; 2009 May;49(1):33-7
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis.
  • We describe a rare case of secondary malignant fibrous histiocytoma (MFH) following Langerhans cell histiocytosis (LCH).
  • A biopsy specimen from the left iliac bone revealed an infiltration of S-100 protein-positive histiocyte-like cells intermingled with eosinophils, which confirmed the diagnosis of eosinophilic granuloma, a type of LCH.
  • Although the patient was treated with prednisolone initially, the disease did not respond well and progressed gradually over time.
  • The patient subsequently received multiple courses of chemotherapy and immunosuppressive therapy with many kinds of anticancer agents for 6 years.
  • He also received radiotherapy totaling 136.8 Gy for lung tumors and osteolytic lesions of the pelvis.
  • Although chemotherapy was continued, the patient died of pneumonia during the neutropenic period following chemotherapy.
  • LCH was not detected histologically in any tissues.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Histiocytosis, Langerhans-Cell / diagnosis
  • [MeSH-minor] Bone Diseases. Eosinophilic Granuloma / diagnosis. Eosinophilic Granuloma / drug therapy. Eosinophilic Granuloma / radiotherapy. Fatal Outcome. Humans. Lung Diseases. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / etiology. Pneumonia. Salvage Therapy / methods. Young Adult

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474515.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Quadros CA, Vasconcelos A, Andrade R, Ramos RS, Studart E, Nascimento G, Trajano A: Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma. Int Semin Surg Oncol; 2006;3:18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma.
  • This article is a case report of a high grade, radio-induced, breast malignant fibrous histiocytoma (undifferentiated high grade pleomorphic sarcoma), which developed in a 44-year old female, seven years after breast conservative surgery and radiotherapy for a T1N0M0 invasive left breast ductal carcinoma.
  • The sarcoma presented as a fast growing tumour, 9.5 cm in the largest diameter, with skin, left breast, chest wall muscle and rib invasion.
  • Neoadjuvant chemotherapy was performed with epirubicin and ifosfamide.
  • Extended radical surgery according to oncological standards and soft tissue reconstruction were carried out.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2068-75 [10070313.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3378-83 [11013278.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):66-72 [7834431.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):356-8 [12383902.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1832-40 [12673708.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):856-63 [15981282.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7 [1648044.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • (PMID = 16824232.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1538603
  •  go-up   go-down


36. Reinecke P, Steckstor M, Schmitz M, Gabbert HE, Gerharz CD: Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart. Oncol Rep; 2004 Mar;11(3):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart.
  • Primary malignant fibrous histiocytoma (MFH) of the heart is a rare and highly malignant soft tissue tumor, which is largely resistant to conventional chemotherapy and radiotherapy.
  • Therefore, we analyzed growth inhibitory effects of different chemotherapeutic agents and mechanisms of drug resistance in the recently established cell line MFH-H derived from a human primary cardiac MFH.
  • The expression and function of multidrug resistance-related proteins, i.e. the P-glycoprotein, the multidrug resistance-associated protein (MRP) and the lung resistance-related protein (LRP) were determined by FACScan and functional assays of cellular drug efflux.
  • The concentration required for a 50% inhibition of growth (IC50) was 0.001 microM for etoposide and 0.035 microM for vincristine.
  • [MeSH-major] Alkaloids / therapeutic use. Drug Resistance, Multiple. Heart Neoplasms / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Plant Extracts / therapeutic use. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Separation. Cell Survival. Cells, Cultured. Coloring Agents / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Etoposide / pharmacology. Flow Cytometry. Humans. Inhibitory Concentration 50. P-Glycoprotein / metabolism. Paclitaxel / pharmacology. Phenotype. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Vault Ribonucleoprotein Particles / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767515.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Coloring Agents; 0 / P-Glycoprotein; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 298-93-1 / thiazolyl blue; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


37. Mevio E, Sbrocca M, Gorini E, Artesi L, Mullace M, Castelli A, Migliorini L: Malignant fibrous histiocytoma of the pharynx. Acta Otorhinolaryngol Belg; 2003;57(1):79-81
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the pharynx.
  • Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life, but is relatively uncommon in the head and neck region.
  • That region has been reported to be the origin of malignant fibrous histiocytoma in 3-10% of cases.
  • Histologically it is sometimes hard to distinguish this tumor from some sarcomas and pleomorphic carcinomas.
  • The treatment of choice is a large surgical resection, while radiotherapy and chemotherapy are reserved for recurrences.
  • The authors present a case of oropharyngeal malignant fibrous histiocytoma.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12642957.001).
  • [ISSN] 0001-6497
  • [Journal-full-title] Acta oto-rhino-laryngologica Belgica
  • [ISO-abbreviation] Acta Otorhinolaryngol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


38. Jebson PJ, Sullivan L, Murray PM, Athanasian EA: Malignant fibrous histiocytoma of the distal radius: a case report. J Hand Surg Am; 2004 Mar;29(2):194-200
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the distal radius: a case report.
  • We report a case of a primary malignant fibrous histiocytoma of the distal radius in a 46-year-old man.
  • Treatment involved en bloc resection, reconstruction with a nonvascularized free fibular autograft, and wrist arthrodesis combined with adjuvant chemotherapy.
  • At the 2-year follow-up evaluation the patient had a satisfactory outcome with complete radiographic union and no evidence of a local recurrence or metastasis.
  • Resection combined with autogenous fibular grafting and adjuvant chemotherapy appears to be an acceptable method for treating malignant fibrous histiocytoma of the distal radius in this patient.
  • [MeSH-major] Bone Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery. Radius
  • [MeSH-minor] Chemotherapy, Adjuvant. Fibula / transplantation. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Reconstructive Surgical Procedures. Transplantation, Autologous

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15043888.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Virgili G, Di Stasi SM, Storti L, Orlandi A, Vespasiani G: Successful management of retroperitoneal malignant fibrous histiocytoma involving both kidneys. Scand J Urol Nephrol; 2000 Jun;34(3):208-10
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of retroperitoneal malignant fibrous histiocytoma involving both kidneys.
  • We report a rare case of a retroperitoneal inflammatory variant of malignant fibrous histiocytoma (MFH) involving both kidneys.
  • The best treatment for MFHs is surgery with radical excision of the tumor.
  • The patient underwent adjuvant chemotherapy and 4 years later survives in a fairly good condition.
  • [MeSH-major] Histiocytoma, Benign Fibrous / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Kidney / pathology. Magnetic Resonance Imaging. Male. Reoperation. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10961478.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWEDEN
  •  go-up   go-down


40. Demiralp B, Erler K, Ozturan EK, Bek D, Ozdemir T, Kurt B: An uncommon presentation of malignant fibrous histiocytoma of the calcaneus. J Am Podiatr Med Assoc; 2007 May-Jun;97(3):218-22
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of malignant fibrous histiocytoma of the calcaneus.
  • Malignant fibrous histiocytoma of bone is the osseous counterpart of the tumor in soft tissue.
  • We describe a primary malignant fibrous histiocytoma of the calcaneal bone in a 21-year-old man.
  • The patient underwent neoadjuvant and adjuvant chemotherapy and below-the-knee amputation, and no local recurrence or metastasis was noted after 2 years of follow-up.
  • [MeSH-major] Bone Neoplasms / pathology. Calcaneus. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507531.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Akhter SA, McGinty J, Konys JJ, Giesting RM, Merrill WH, Wagoner LE: Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation. J Heart Lung Transplant; 2004 Dec;23(12):1447-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation.
  • Malignant fibrous histiocytoma (MFH) is an extremely rare primary cardiac tumor.
  • We describe a young patient who underwent orthotopic heart transplantation for an unresectable right ventricular MFH and presented 7 years later with a local recurrence in the native right atrium.
  • This was treated by complete resection of the right atrial tumor and adjuvant chemotherapy.
  • [MeSH-major] Heart Neoplasms / surgery. Heart Transplantation. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607678.001).
  • [ISSN] 1053-2498
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Douya H, Yokoyama R, Beppu Y, Hasegawa T: Malignant fibrous histiocytoma associated with diaphyseal medullary stenosis. Clin Orthop Relat Res; 2002 Jul;(400):211-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma associated with diaphyseal medullary stenosis.
  • An unusual presentation of secondary malignant fibrous histiocytoma of the femur in a patient with diaphyseal medullary stenosis is described.
  • The patient, a 42-year-old man, presented with a painful lump in the right knee.
  • After chemotherapy, surgical resection was done.
  • On light microscopic examination, the tumor had features characteristic of malignant fibrous histiocytoma.
  • The patient's aunt had died of a bone sarcoma in the shoulder region.
  • It is important to recognize this extremely rare clinicopathologic type of diaphyseal medullary stenosis that frequently is associated with secondary high-grade sarcomas.
  • [MeSH-major] Femoral Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072764.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Neda H, Maeda M, Moriya H, Inohara T, Fujita T, Doi T, Nakajima T, Tanaka I, Ohhira N, Takeda M, Gotoh M: [A case of retroperitoneal malignant fibrous histiocytoma with marked response to cisplatin, ifosfamide and doxorubicin]. Gan To Kagaku Ryoho; 2001 Jun;28(6):849-53
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant fibrous histiocytoma with marked response to cisplatin, ifosfamide and doxorubicin].
  • A 61-year-old man was admitted to our hospital in December 1994 for a suspected retroperitoneal tumor.
  • Systemic imaging investigations demonstrated retroperitoneal solid tumor, which was diagnosed as malignant fibrous histiocytoma (MFH) by immunohistochemistry for alpha 1-antitrypsin.
  • In March 1995, he was treated with 3 courses of systemic chemotherapy with cisplatin, ifosfamide and doxorubicin followed by the same therapy in March 1996, without serious side effects.
  • MFH is known to be resistant to ordinary chemotherapy.
  • However, the CT showed a marked decrease in the size of the tumor, and the tumor disappeared within 2 months after the first treatment.
  • The present chemotherapy may be an effective treatment for retroperitoneal MFH.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432357.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


44. Tanaka F, Li M, Hanaoka N, Bando T, Fukuse T, Hasegawa S, Wada H: Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg; 2005 May;79(5):1711-4; discussion 1714-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The pathologic diagnoses of pulmonary nodules were pulmonary metastases of breast cancer in 39 patients, primary lung cancer in 6, and other diagnoses in 7 (tuberculosis and hamartoma in 2 each; sclerosing hemangioma, organizing pneumonia, and paragohimiasis in 1 each).
  • The 5-year survival rate after pulmonary metastectomy of metastatic breast cancer patients was 30.8%, which was not better than those documented in metastatic breast cancer patients treated with modern chemotherapy.
  • CONCLUSIONS: Pulmonary metastectomy may not be the primary therapeutic option in metastatic breast cancer patients, and patients should be treated principally with chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854960.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: Primary malignant fibrous histiocytoma of the thyroid. Eur J Surg Oncol; 2009 Jun;35(6):649-53
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the thyroid.
  • AIMS AND METHODS: To study the clinical features, diagnosis, and treatment of primary malignant fibrous histiocytoma of the thyroid (MFH-T).
  • Treatment and outcome were analyzed retrospectively in a consecutive series of 12 patients with primary MFH-T treated at the Cancer Hospital of the Chinese Academy of Medical Sciences from 1987 to 2007.
  • Two patients were given post-operative chemotherapy.
  • Six patients died six months after treatment, and the other four patients died in 10, 14, 18, and 24 months after treatment, respectively.
  • Nine patients died of the disease, and one patient died of cerebral hemorrhage after treatment.
  • Although surgical resection of MFH-T is the treatment of choice in MFH-T, the results are unsatisfactory.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922667.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Milicic D, Juretic A, Bulum J, Saric N, Bisof V, Jelic I, Jelasic D: Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases. J Card Surg; 2007 Nov-Dec;22(6):513-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases.
  • Malignant fibrous histiocytoma is an extremely rare primary malignant tumor of the heart.
  • The prognosis is poor with an average survival time of one year.
  • We report a case of recurrent left atrial malignant fibrous histiocytoma initially misdiagnosed as myxoma.
  • The patient underwent repeated surgical resections followed by chemotherapy.
  • Despite adjuvant chemotherapy, 18 months after initial diagnosis, definitive tumor relapse in left atrium was diagnosed.
  • This is the 48th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Muscle Neoplasms / diagnosis. Muscle, Skeletal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039217.001).
  • [ISSN] 0886-0440
  • [Journal-full-title] Journal of cardiac surgery
  • [ISO-abbreviation] J Card Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Shields JA, Husson M, Shields CL, Krema H, Eagle RC Jr, Singh AD: Orbital malignant fibrous histiocytoma following irradiation for retinoblastoma. Ophthal Plast Reconstr Surg; 2001 Jan;17(1):58-61
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital malignant fibrous histiocytoma following irradiation for retinoblastoma.
  • PURPOSE: An unusual case is reported of orbital malignant fibrous histiocytoma that developed after irradiation for retinoblastoma.
  • RESULTS: A 5-month-old girl underwent enucleation of the left eye, external beam irradiation of the right eye, and systemic chemotherapy for bilateral sporadic retinoblastoma.
  • At age 17 years, a malignant fibrous histiocytoma developed in the medial aspect of the orbit and nasal cavity.
  • CONCLUSIONS: Although orbital fibrous histiocytoma occurs usually as a primary tumor of adulthood, it can also develop as a secondary tumor after irradiation for retinoblastoma.
  • [MeSH-major] Histiocytoma, Benign Fibrous / etiology. Neoplasms, Radiation-Induced / etiology. Orbital Neoplasms / etiology. Retinal Neoplasms / radiotherapy. Retinoblastoma / radiotherapy

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11206748.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Macák J, Smardová J, Zavrelová I, Vránová V, Kuglík P: Malignant fibrous histiocytoma of the parotid gland. Cesk Patol; 2007 Oct;43(4):148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the parotid gland.
  • We described a rare malignant fibrous histiocytoma of the parotid gland (MFH) in a 63-year-old woman.
  • During six months the tumour size became 10 cm in diameter with skin ulceration.
  • The histology revealed a storiform-pleomorphic type of MFH with high mitotic rate.
  • The patient died shortly after the beginning of chemotherapy.
  • In view of short course of disease we lack the data about the influence of the non-mutated p53 gene on the prognosis and therapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188922.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


49. Akai T, Yamamoto K, Iida T, Iizuka H, Nojima T: Malignant fibrous histiocytoma in the craniocervical junction presenting with severe occipitalgia. Brain Tumor Pathol; 2006 Oct;23(2):101-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma in the craniocervical junction presenting with severe occipitalgia.
  • The tumor demonstrated no definitive sarcoma differentiation and was identified as malignant fibrous histiocytoma.
  • After tumor resection, the patient received adjuvant radiation and chemotherapy.
  • Chemotherapy with ifosfamide, cisplatin, and etoposide caused remarkable tumor reduction, but suspension of chemotherapy resulted in tumor recurrence.
  • The results of our drug protocol suggest that this regimen is feasible as postoperative adjuvant chemotherapy for malignant fibrous histiocytoma.
  • The role of adjuvant chemotherapy and radiation therapy for this highly malignant rare tumor should be evaluated in a prospective study with precise histological diagnosis.
  • [MeSH-major] Atlanto-Occipital Joint / pathology. Head and Neck Neoplasms / pathology. Headache / etiology. Histiocytoma, Malignant Fibrous / pathology
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Fracture Fixation. Humans. Magnetic Resonance Imaging. Middle Aged. Neck Muscles / pathology. Neurosurgical Procedures. Occipital Lobe. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095127.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, Pisters PW: Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer; 2001 Sep 15;92(6):1550-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
  • BACKGROUND: The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas.
  • METHODS: The medical records of 43 consecutive patients with soft tissue or bone sarcomas who were treated with concurrent IFX and EBRT were reviewed.
  • Histologies were rhabdomyosarcoma (n = 16 patients), Ewing sarcoma (n = 10 patients), malignant fibrous histiocytoma (n = 9 patients), and other soft tissue sarcomas (n = 8 patients).
  • Treatment consisted of EBRT (median dose, 50.4 gray [Gy]) with concomitant IFX (median dose per cycle, 10.2 g/m(2)).
  • All patients with Ewing sarcoma or rhabdomyosarcoma received additional concurrent chemotherapy.
  • Confluent moist desquamation (Grade 3) occurred in nine patients in the treatment field; no patient experienced Grade 4 local toxicity.
  • CONCLUSIONS: Local and systemic toxicities after the administration of therapeutic doses of IFX with concomitant EBRT appear comparable to those observed with either treatment alone.
  • These results support the design of prospective studies evaluating concurrent ifosfamide and radiation therapy for patients with sarcomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Bone Neoplasms / therapy. Ifosfamide / administration & dosage. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Histiocytoma, Benign Fibrous / therapy. Humans. Infant. Male. Middle Aged. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745234.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 27
  •  go-up   go-down


51. Cağlar K, Güngör S, Akansoy S, Sakalli U, Orhan D, Cağlar M: Successful treatment of retroperitoneal giant cell-type malignant fibrous histiocytoma in a 5-year-old boy. Turk J Pediatr; 2007 Jul-Sep;49(3):307-11
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of retroperitoneal giant cell-type malignant fibrous histiocytoma in a 5-year-old boy.
  • Malignant fibrous histiocytoma, usually seen in patients older than 10 years, is an aggressive soft-tissue sarcoma occurring mostly in the extremities and the trunk, but it is extremely rare in children.
  • We report the clinical, radiological and pathologic features of a five-year-old boy who was diagnosed as a retroperitoneally originated malignant fibrous histiocytoma.
  • The patient with unresectable mass was successfully treated with multidisciplinary approach, with chemotherapy, surgery and radiotherapy, by using combined chemotherapy consisting of vincristine, cisplatinum, adriamycin, cyclophosphamide, actinomycin D and dacarbazine.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990587.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


52. Xiao JY, Ye ZX, Wang SL, Wang LS: [Value of imaging in the diagnosis of primary malignant fibrous histiocytoma of bone]. Zhonghua Zhong Liu Za Zhi; 2005 Jun;27(6):364-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of imaging in the diagnosis of primary malignant fibrous histiocytoma of bone].
  • OBJECTIVE: To investigate the imaging feature of primary malignant fibrous histiocytoma of the bone (PBMFH) by the conventional radiography, CT and MRI, and to evaluate these different imaging methods in its diagnosis.
  • The common imaging appearance on the conventional radiography and CT were eccentric, aggressive, osteolytic destructions of various types located at the ends of extremities with extraosseous soft tissue masses, but periosteal reaction was rare.
  • CONCLUSION: Primary malignant bone fibrous histiocytoma, a rare primary malignant bone tumor, is most frequently located in the long bone.
  • CT and MRI are quite important in demonstrating the details and extent of the disease such as soft tissue, cortical destruction, periosteal reaction, calcification and necrosis.
  • Furthermore, MRI may also be valuable in assessing the efficacy of chemotherapy and/or radiation therapy, as well as in distinguishing recurrence from postoperative or post-radiation changes.
  • [MeSH-major] Bone Neoplasms / diagnosis. Histiocytoma, Malignant Fibrous / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117901.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Salemis NS, Gourgiotis S, Tsiambas E, Panagiotopoulos N, Karameris A, Tsohataridis E: Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor. J Gastrointest Cancer; 2010 Dec;41(4):238-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intra-abdominal malignant fibrous histiocytoma: a highly aggressive tumor.
  • BACKGROUND AND PURPOSE: Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life occurring predominantly in the extremities.
  • The aim of this study is to describe a very rare case of an intra-abdominal MFH with a highly aggressive clinical course.
  • METHODS: A 67-year-old male was referred to our department with a 2-week history of dull lower abdominal pain and a gradually enlarging right lower abdominal mass, which he first noticed 2 months prior to admission.
  • Computed tomography (CT) scan demonstrated a mass in the right iliac fossa.
  • One month after surgery, while on adjuvant chemotherapy, the patient was readmitted with dyspnea and a slightly palpable mass in the area of the previous radical resection.
  • Unfortunately, despite treatment, the patient died of progressive disease 5 weeks later.
  • CONCLUSIONS: Primary intra-abdominal MFH is a very rare but aggressive malignancy with a high tendency of local recurrence and metastatic spread.
  • Early detection and complete surgical excision with clear margins is the treatment of choice.
  • In some cases, however, the tumor can exhibit a highly aggressive clinical course despite radical surgery and adjuvant therapy.
  • [MeSH-major] Abdomen / pathology. Histiocytoma, Malignant Fibrous / secondary. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):499-505 [1845950.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2098-103 [1311983.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1299-302 [17451221.001]
  • [Cites] Gastrointest Radiol. 1988 Oct;13(4):299-305 [2844619.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Surg Today. 2003;33(10 ):794-6 [14513333.001]
  • [Cites] Surg Today. 2002;32(12):1091-5 [12541030.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] World J Gastroenterol. 2007 Dec 21;13(47):6441-3 [18081238.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Clin Imaging. 1998 Nov-Dec;22(6):408-13 [9876909.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Dig Surg. 1999;16(5):425-30 [10567806.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 22;3:15 [16792809.001]
  • [Cites] Int J Gastrointest Cancer. 2005;36(2):105-12 [16648661.001]
  • (PMID = 20419356.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Pérez AF, Muñoz R, Morales J, Fereira E, Colina-Chourio J: [Transversal laryngotomy. Oncologic and functional results in laryngeal sarcoma. (Malignant fibrous histiocytoma). Case report and literature review]. Invest Clin; 2008 Mar;49(1):103-10
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transversal laryngotomy. Oncologic and functional results in laryngeal sarcoma. (Malignant fibrous histiocytoma). Case report and literature review].
  • [Transliterated title] Presentación de un caso de sarcoma maligno laríngeo, tratado mediante laringotomía transversa y revisión de la literatura.
  • Sarcomas of the larynx are rare neoplasmas that consitute less than 1% of laryngeal malignancies, and their usual treatment is surgery including partial and total laryngectomy and endoscopic laser cordotomy with reported 20% recurrence.
  • Due to previous positive experience from transversal laryngotomy in patients who underwent aritenoidectomy to treat bilateral cord paralysis after total thyroidectomy, the purpose of this work was to report on the surgical treatment of this rare case with such technique.
  • Thus, a 47 year-old physician who complained of hoarseness for four months without dyspnea, stridor, or dysphagia and with no history of irradiation or chemotherapy was operated after both endoscopic and tomographic studies showed a 3 to 4 cm glotic tumor in its right side, with no ulceration.
  • The pathology proved to be malignant fibrous histiocytoma.

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18524336.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Venezuela
  • [Number-of-references] 24
  •  go-up   go-down


55. Atalar H, Başarir K, Yildiz Y, Sağlik Y: [Prognostic factors in patients with malignant fibrous histiocytoma of the extremities]. Acta Orthop Traumatol Turc; 2007 Aug-Oct;41(4):271-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with malignant fibrous histiocytoma of the extremities].
  • OBJECTIVES: We evaluated prognostic factors in patients with malignant fibrous histiocytoma of the extremity.
  • METHODS: The study included 26 patients (22 males, 4 females; 15 patients < age 60) with a diagnosis of malignant fibrous histiocytoma of the extremity.
  • Clinical and pathological data were analyzed including age, gender, affected extremity, presentation status (primary or recurrent), localization (proximal or distal), size, depth, and grade of the tumor, resection quality, adjuvant therapy, and the presence of distant metastasis at the time of diagnosis.
  • Adjuvant chemotherapy and radiotherapy were administered to 17 patients and 10 patients, respectively.
  • Two patients had distant metastasis at the time of diagnosis while eight patients developed distant metastasis within a mean of 13 months (range 7 to 20 months) postoperatively.
  • CONCLUSION: Patients with high-grade malignant fibrous histiocytoma have a poorer prognosis.
  • [MeSH-major] Extremities. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Recurrence, Local / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180555.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


56. Natarajan MV, Mohanlal P, Bose JC: Limb salvage surgery complimented by customised mega prostheses for malignant fibrous histiocytomas of bone. J Orthop Surg (Hong Kong); 2007 Dec;15(3):352-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage surgery complimented by customised mega prostheses for malignant fibrous histiocytomas of bone.
  • PURPOSE: To assess functional and oncological outcomes of patients with malignant fibrous histiocytomas of bone, after limb salvage surgery complimented by a customised prosthesis.
  • METHODS: Between May 1991 and December 2002, 15 men and 5 women (mean age, 42 years) with histologically proven malignant fibrous histiocytoma of bone underwent treatment involving limb salvage surgery complimented by a customised mega prosthesis.
  • The Kaplan-Meier 5-year survival rates of the patients treated without chemotherapy and with chemotherapy were 50% and 76%, respectively.
  • CONCLUSION: Limb salvage surgery with chemotherapy is a viable treatment option for patients with malignant fibrous histiocytoma of bone.
  • Such therapy improves quality of life and provides a useful and functional limb.
  • [MeSH-major] Bone Neoplasms / surgery. Histiocytoma, Malignant Fibrous / surgery. Limb Salvage. Prostheses and Implants
  • [MeSH-minor] Adolescent. Adult. Amputation. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162685.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Okamoto K, Kato S, Katsuki S, Wada Y, Toyozumi Y, Morimatsu M, Aoyagi S, Imaizumi T: Malignant fibrous histiocytoma of the heart: case report and review of 46 cases in the literature. Intern Med; 2001 Dec;40(12):1222-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the heart: case report and review of 46 cases in the literature.
  • A rare case of cardiac malignant fibrous histiocytoma (MFH) is reported.
  • Neither chemotherapy nor irradiation was administered.
  • The details of this case are presented with a review of the literature.
  • [MeSH-major] Heart Neoplasms / diagnosis. Histiocytoma, Benign Fibrous / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11813848.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 57
  •  go-up   go-down


58. Abe T, Yamanaka K, Nakata W, Mori N, Sekii K, Yoshioka T, Itatani H: [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report]. Hinyokika Kiyo; 2007 Apr;53(4):241-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report].
  • A 42-year-old male was referred to our hospital with a complaint of right lumbar pain in September 1999.
  • Abdominal computed tomography and magnetic resonance imaging revealed a large retroperitoneal tumor adjacent to the aorta and the renal vessels.
  • Histopathological examination showed a malignant fibrous histiocytoma (MFH).
  • Two cycles of systemic chemotherapy with pirarubicin, vincritine and cyclophosphamide were ineffective, then we tried concurrent cisplatin and radiation therapy.
  • Chemoradiation therapy showed a marked decrease in the size of the tumor, and the patient also recovered from right lumbar pain without serious side effects.
  • After chemoradiation therapy, we performed tumorectomy.
  • We performed repeatedly concurrent cisplatin and radiation therapy for the recurrent and metastatic tumor sites, and chemoradiation therapy led to regression of the tumors every time.
  • Concurrent cisplatin and radiation therapy might be an effective treatment for unresectable MFH.
  • [MeSH-major] Cisplatin / therapeutic use. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515074.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Su HW, Hsu CS, Lin YH, Hsu MI, Chiang HK, Chou SY: Malignant fibrous histiocytoma during pregnancy: a case report. Taiwan J Obstet Gynecol; 2006 Mar;45(1):86-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma during pregnancy: a case report.
  • OBJECTIVE: We present a case of a 38-year-old postpartum woman who had antepartal undiagnosed sarcoma with multiple metastasis.
  • Although the patient underwent aggressive treatment with surgery and chemotherapy, she died 3 months after the vaginal delivery of a healthy female infant weighing 2,090 g at 35 weeks of gestation.
  • All the removed specimens were sent for pathologic examination, and the results showed a sarcoma favoring malignant fibrous histiocytoma with its primary origin in the left atrium.
  • [MeSH-major] Bone Neoplasms / secondary. Heart Neoplasms / pathology. Histiocytoma, Malignant Fibrous / secondary. Humerus. Pregnancy Complications, Neoplastic. Shoulder Joint
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Female. Heart Atria. Humans. Infant, Newborn. Postpartum Period. Pregnancy. Pregnancy Trimester, Third. Tomography, X-Ray Computed


60. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the abdominal cavity: report of a case.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Matsumoto S, Ahmed AR, Kawaguchi N, Manabe J, Matsushita Y: Results of surgery for malignant fibrous histiocytomas of soft tissue. Int J Clin Oncol; 2003 Apr;8(2):104-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgery for malignant fibrous histiocytomas of soft tissue.
  • BACKGROUND: To address the prognosis and the role of surgery in the management of patients with malignant fibrous histiocytoma (MFH), strict definition and accurate evaluation of local recurrence is mandated, together with adequate gross and microscopic evaluation of the achieved surgical margins.
  • adjuvant chemotherapy, (4). size, (5).
  • RESULTS: Local recurrence after primary surgery done at the authors' institute was the most significant prognostic factor, where 20 of 123 patients developed local recurrence ( P < 0.0001).
  • The local recurrence rate for each surgical procedure was 75% for intralesional, 44.4% for marginal, 30.8% for inadequate wide, 12.3% for adequate wide, and 5% for curative procedures.
  • In patients with a history of recurrent tumor or infiltrative pattern, local recurrence was not observed after a curative procedure, but occurred even after an adequate wide procedure.
  • An adequate wide procedure for primary tumors and a curative procedure for recurrent tumors and tumors with an infiltrative pattern provide safe surgical margins.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Reoperation. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12720103.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Okada Y, Akisue T, Hara H, Kishimoto K, Kawamoto T, Imabori M, Kishimoto S, Fukase N, Onishi Y, Kurosaka M: The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model. Anticancer Res; 2010 Sep;30(9):3391-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model.
  • The effect of bevacizumab was evaluated on malignant fibrous histiocytoma (MFH) in vivo using an animal model.
  • MATERIALS AND METHODS: MFH cell line, NaraH, was implanted to athymic nude mice which were randomly divided into a treatment and a control group.
  • The change in body weight and tumour volume were evaluated and immunohistochemical analysis was performed of microvessel density (MVD) and VEGF expression in the tumour tissue.
  • Intratumoural MVD was significantly decreased in the bevacizumab treatment group compared to the control group.
  • The current study suggests that bevacizumab may be a novel therapeutic agent for MFH.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Histiocytoma, Malignant Fibrous / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Bevacizumab. Disease Models, Animal. Humans. Immunohistochemistry. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Pathologic / drug therapy. Plant Extracts. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944113.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Plant Extracts; 0 / U & D Sweet Bitter; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


63. Yu H, Wang CF, Yang WT, Zhu XZ: [Angiomatoid fibrous histiocytoma: report of 5 cases with review of literature]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):245-8
Genetic Alliance. consumer health - Histiocytoma, angiomatoid fibrous.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiomatoid fibrous histiocytoma: report of 5 cases with review of literature].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of angiomatoid fibrous histiocytoma (AFH).
  • The patients primarily presented with a slowly enlarging painless deep dermal or subcutaneous mass.
  • The patients underwent complete resection of the tumor, with no adjuvant chemotherapy and/or radiotherapy given.
  • Gross examination showed that the tumor was well-circumscribed and had a grey-colored cut surface, with focal hemorrhagic cystic changes.
  • Histologically, the tumor was composed of histiocytoid or spindly cells arranged in nodular pattern.
  • Fibrillary neuropil-type intercellular material was identified in all cases and a fibrous pseudocapsule surrounded by lymphocytes and plasma cells was demonstrated in 3 cases.
  • Immunohistochemical study showed that all of them were positive for vimentin and negative for S-100 protein, pan-cytokeratin, CD34 and CD31.
  • Definitive diagnosis requires thorough histologic examination and clinical correlation.
  • Wide local excision with post-operative follow up is the main modality of treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aneurysm / metabolism. Aneurysm / pathology. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Chemotherapy, Adjuvant. Child. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Histiocytoma, Malignant Fibrous / pathology. Humans. Male. Radiotherapy, Adjuvant. Vimentin / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654123.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Desmin; 0 / Vimentin
  •  go-up   go-down


64. Goto T, Okuma T, Nakada I, Hozumi T, Kondo T: [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1750-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative adjuvant therapy for primary malignant bone tumors].
  • In primary bone sarcomas, the efficacy of chemotherapy varies according to the histological types.
  • However, because these sarcomas are chemosensitive, their prognoses have been improved with adjuvant chemotherapy.
  • Nowadays, in highgrade bone sarcomas, especially in osteosarcoma, Ewing.s sarcoma and malignant fibrous histiocytoma of bone, adjuvant chemotherapy including neoadjuvant or preoperative chemotherapy is usually performed.
  • The purpose of the neoadjuvant chemotherapy is (I) to prevent distant metastases, (II) to reduce the size of the primary tumor and (III) to evaluate the efficacy of the chemotherapeutic agents.
  • Evaluating the efficacy of the chemotherapeutic agents in preoperative chemotherapy facilitates rational selection of postoperative chemotherapeutic agents.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate and vincristine in osteosarcoma, and vincristine, adriamycin, cyclophosphamide, ifosfamide, actinomycin-D and etoposide in Ewing's sarcoma.
  • In contrast, chondrosarcomas are chemoresistant, and chemotherapy is rarely performed.
  • Low-grade bone sarcomas, e. g., parosteal osteosarcoma, central low-grade osteosarcoma, are well cured only by surgical excision, and adjuvant chemotherapy is not performed for these low-grade sarcomas.
  • To enhance the efficacy of preoperative chemotherapy, various modalities have been used e. g., intraarterial infusion, caffeine-assisted chemotherapy, and local perfusion with hyperthermia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030009.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VAC protocol; VACA protocol; VAIA protocol
  •  go-up   go-down


65. Dorobantu M, Fruntelata A, Constantinescu D, Racoveanu I, Ardeleanu C, Tatu-Chitoiu G, Lazar IC: Primary left heart malignant fibrous histiocytoma. Eur J Echocardiogr; 2005 Jun;6(3):225-7
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary left heart malignant fibrous histiocytoma.
  • We present the case of a 53 years-old woman presenting with congestive heart failure and pleural and pericardial effusions, in whom transthoracic and transesophageal echocardiography revealed multilocular cardiac tumor involving the left atrium wall, extending into the pericardium.
  • Tumor was excised surgically and proved to be a malignant fibrous histiocytoma, primarily confined to the heart.
  • Despite surgery followed by chemotherapy, the patient died a few months later.
  • This is the 47th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • [MeSH-major] Echocardiography. Heart Neoplasms / ultrasonography. Histiocytoma, Benign Fibrous / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894243.001).
  • [ISSN] 1525-2167
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Wen J, Wang XY, Luo CY, Jiang GS, Wang LJ, Chen YW: [Benign fibrous histiocytoma involving the skull: a case report and literature review]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec;30(12):2752-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign fibrous histiocytoma involving the skull: a case report and literature review].
  • OBJECTIVE: Benign fibrous histiocytomas (BFH) represent a rare group of tumors with a common origin from the tissue histiocytes, often causing pain and space-occupying effect.
  • BFH of bone causes diagnostic difficulties due to its atypical clinical symptoms, radiographic features and cytological characteristics, which can be easily confused with other benign lesions such as non-ossifying fibroma (NOF), giant cell tumor (GCT), and fibrous dysplasia.
  • The lesions are prone to relapse, and the patients often show poor response to radiotherapy and chemotherapy, therefore radical lesion resection should be the therapeutic target of this disease.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Skull / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21177160.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


67. Jarry J, Belleannee G, Laurent C, Coindre JM, Evrard S: Primary malignant fibrous histiocytoma of the pancreas: benefit of the multidisciplinary approach. Eur J Gastroenterol Hepatol; 2010 Jun;22(6):765-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the pancreas: benefit of the multidisciplinary approach.
  • Primary malignant fibrous histiocytoma (MFH) is an exceedingly rare tumour of the pancreas with a high recurrence rate and a poor prognosis.
  • In this report, the authors present the case of a 45-year-old man who was first operated on for a primary MFH of the pancreas.
  • Eleven months after the surgery, he was diagnosed with a tumoural recurrence presenting as hepatic and pulmonary metastasis.
  • The patient underwent a multidisciplinary treatment of chemotherapy, percutaneous radiofrequency ablation, and a right hepatectomy combined with intraoperative radiofrequency ablation.
  • Under multidisciplinary treatment, the patient fully recovered.
  • We report a case of a primary MFH of the pancreas treated by using a multidisciplinary approach resulting in an above average survival rate.
  • Although further cases and longer follow-up periods are necessary to conclude about the role of multidisciplinary treatment in the long-term prognosis of primary MFH of the pancreas, we believe that multidisciplinary treatment could improve the survival rates of other patients.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Histiocytoma, Malignant Fibrous / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446353.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Kitazono I, Saigenji H: [Long-term survival of malignant fibrous histiocytoma of the chest wall by multidisciplinary treatment]. Kyobu Geka; 2007 Mar;60(3):221-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival of malignant fibrous histiocytoma of the chest wall by multidisciplinary treatment].
  • We report a case of malignant fibrous histiocytoma (MFH) of the chest wall.
  • Chest computed tomography (CT) revealed a tumor located at right posterior chest wall.
  • In May 1997, resection of the tumor was done (the 3rd operation), but metastasis to the ribs (the 4th operation), subcutaneous tissue (the 5th operation), and local recurrence (the 6th operation) was found within 4 years postoperatively.
  • Resection was done for each metastasis, and postoperative radiotherapy (66 Gy) and chemotherapy (CYVADIC) were done.
  • Multidisciplinary treatment may provide longer survival for patients with MFH of the chest wall.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Malignant Fibrous / therapy. Thoracic Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Radiotherapy Dosage. Surgical Mesh. Survivors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352141.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CYVADIC protocol
  •  go-up   go-down


69. Pardini RS, Wilson D, Schiff S, Bajo SA, Pierce R: Nutritional intervention with omega-3 Fatty acids in a case of malignant fibrous histiocytoma of the lungs. Nutr Cancer; 2005;52(2):121-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional intervention with omega-3 Fatty acids in a case of malignant fibrous histiocytoma of the lungs.
  • We present a case of a 78-yr-old man with malignant fibrous histiocytoma with multiple lesions in both lungs.
  • Following diagnosis, he declined conventional chemotherapy and elected nutritional intervention by increasing intake of omega-3 fatty acids and lowering intake of omega-6 fatty acids.
  • Serial computed tomography scans and pulmonary x-rays revealed remarkably a slow and steady decrease in the size and number of bilateral nodules.
  • [MeSH-major] Fatty Acids, Omega-3 / therapeutic use. Histiocytoma, Malignant Fibrous / diet therapy. Lung Neoplasms / diet therapy
  • [MeSH-minor] Aged. Disease Progression. Docosahexaenoic Acids / therapeutic use. Eicosapentaenoic Acid / therapeutic use. Fish Oils. Humans. Male

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201843.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fish Oils; 25167-62-8 / Docosahexaenoic Acids; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


70. Sachse F, August C, Alberty J: [Malignant fibrous histiocytoma in the parotid gland. Case series and literature review]. HNO; 2006 Feb;54(2):116-20
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma in the parotid gland. Case series and literature review].
  • BACKGROUND: Malignant fibrous histiocytoma (MFH), a soft tissue sarcoma that is predominantly localized in the extremities and retroperitoneum, rarely occurs in the head and neck.
  • Surgical therapy was the first treatment of choice.
  • In two cases, post-surgical treatment involved radiation and/or chemotherapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Histiocytoma, Malignant Fibrous / therapy. Parotid Neoplasms / diagnosis. Parotid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):1-7 [1624288.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] J Clin Pathol. 1982 Sep;35(9):946-53 [6288775.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] HNO. 2006 Feb;54(2):116-20 [15891863.001]
  • [Cites] HNO. 2004 Jun;52(6):497-502 [15133615.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):463-6 [10918180.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Am J Surg. 1986 Oct;152(4):386-92 [3766868.001]
  • [Cites] Laryngoscope. 1981 Dec;91(12):2053-70 [6275219.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1305-15 [3742455.001]
  • [Cites] Histopathology. 1987 Apr;11(4):433-7 [3036682.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Oct;114(10 ):1149-56 [2843204.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1568-76 [12855264.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3135-46 [11753993.001]
  • [Cites] Laryngoscope. 1977 Sep;87(9 Pt 1):1479-99 [197358.001]
  • [Cites] Otolaryngol Head Neck Surg. 1987 Apr;96(4):362-5 [3035462.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Mar;117(3):302-6 [1998570.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2198-201 [3008978.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1070-5 [12782825.001]
  • (PMID = 15891863.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


71. Jin GP, Zhao M, Qi JX, Jiang HG, Yu SG: [Malignant fibrous histiocytoma of head and neck: clinical analysis of 21 cases]. Ai Zheng; 2003 May;22(5):523-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of head and neck: clinical analysis of 21 cases].
  • BACKGROUND & OBJECTIVE: Malignant fibrous histiocytoma (MFH) is a type of pleomorphic neoplastic diseases with complex pathological structure.
  • This study was designed to investigate the clinical and pathological features and improve the diagnosis and treatment.
  • Amplified radical surgery is the first choice of treatment.
  • Radiotherapy alone or chemotherapy alone is not effective to MFH of head and neck region.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12753717.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Bodner K, Bodner-Adler B, Mayerhofer S, Grünberger W, Wierrani F, Czerwenka K, Leodolter S, Mayerhofer K: Malignant fibrous histiocytoma (MFH) of the mesentery: a case report. Anticancer Res; 2002 Mar-Apr;22(2B):1169-70
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma (MFH) of the mesentery: a case report.
  • BACKGROUND: Primary tumors of the mesentery are rare; only a few cases of malignant fibrous histiocytoma have been reported in the literature.
  • This case report presents the management of a patient with malignantfibrous histiocytoma of the mesentery.
  • The tumor was histologically classified as a malignant fibrous histiocytoma, showing a heterologeous picture consisting of large, multinucleated cells and spindle-shaped cells forming a storiform-like growth pattern.
  • A radical excision of the tumor and the lymphnodes was performed and the patient received adjuvant irradiation therapy.
  • Approximately three months later she presented with a great multilobated pelvic mass infiltrating the uterus and the adnexa.
  • CONCLUSION: Malignant fibrous histiocytoma of the mesentery is an extremely rare, highly malignant neoplasm with early metastatic spread.
  • The treatment of choice is wide surgical excision, while the role of adjuvant chemotherapy and irradiation still remains controversiaL
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Mesentery / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12168919.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


73. Gruttadauria S, Doria C, Minervini MI, Doyle HR, Mandalà L, Foglieni CS, Panarello G, Lauro A, Agostara B, Marino IR: Malignant fibrous histiocytoma of the gallbladder: case report and review of the literature. Am Surg; 2001 Jul;67(7):714-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the gallbladder: case report and review of the literature.
  • Malignant fibrous histiocytoma is a soft tissue sarcoma of mesenchymal origin.
  • Here we report the sixth documented case of malignant fibrous histiocytoma of the gallbladder, and we review all other cases reported.
  • The outcome of the visceral sarcomas is poor when compared with tumors arising from the soft tissues.
  • The treatment of primary malignant fibrous histiocytomas of the gallbladder is surgery.
  • In contrast to tumors arising from the extremities the role of adjuvant radiotherapy and chemotherapy is less clear in the case of retroperitoneal and visceral sarcomas.
  • [MeSH-major] Gallbladder Neoplasms. Histiocytoma, Benign Fibrous

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450796.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


74. Alkatan HM, Maktabi A: Malignant fibrous histiocytoma in a patient with history of treated retinoblastoma. Saudi J Ophthalmol; 2010 Jan;24(1):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma in a patient with history of treated retinoblastoma.
  • The histopathology showed a moderately differentiated tumor with vitreous seeding and he received chemotherapy in addition to radiotherapy to his right eye.
  • He presented 20 years later with a right orbital tumor, frozen globe and proptosis.
  • The excisional biopsy of his orbital mass revealed a spindle cell sarcoma with features of malignant fibrous histiocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23960869.001).
  • [ISSN] 1319-4534
  • [Journal-full-title] Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
  • [ISO-abbreviation] Saudi J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3729799
  • [Keywords] NOTNLM ; Orbit / Retinoblastoma / Second tumors
  •  go-up   go-down


75. Seper L, Schwab R, Kiattavorncharoen S, Büchter A, Bánkfalvi A, Joos U, Piffkó J, Kruse-Loesler B: Malignant fibrous histiocytoma of the face: report of a case. Head Face Med; 2007;3:36
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the face: report of a case.
  • BACKGROUND: Soft tissue sarcomas in the head and neck region are rare and often present a difficult differential diagnosis.
  • The aim of our presentation is to point out the complexity of the diagnosis, treatment and follow up.
  • CASE PRESENTATION: An eighty-seven year old female patient was referred to our unit with a fast growing brownish lump on the face.
  • Four months beforehand, a benign fibrous histiocytoma (BFH) had been removed from the same location by excision biopsy with wide tumour-free resection margins.
  • Excision biopsy of the recurrent lesion revealed a malignant fibrous histiocytoma (MFH).
  • Radical tumour resection was completed by extended parotidectomy and neck dissection; the skin defect was covered by a regional bi-lobed flap.
  • No adjuvant radio- or chemotherapy was administered.
  • DISCUSSION: Malignant transformation of BFH is extremely rare and if so, extended radical surgery may give a fair chance for a favourable outcome even in patients with advanced age.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / surgery. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neck Dissection / methods. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):668-76 [8017561.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • (PMID = 17945018.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211745
  •  go-up   go-down


76. Yamate J, Kotera T, Kuwamura M, Kotani T: Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines. Exp Toxicol Pathol; 2007 Apr;58(5):299-309
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines.
  • Histological modulations in tumor cells treated with anti-cancer drugs have been reported.
  • The histogenesis of malignant fibrous histiocytoma (MFH) remains elusive.
  • MT-10 developed tumors of a storiform pattern, while MT-10R and MT-PR tumors comprise round or polygonal cells arranged in a compact sheet.
  • Cisplatin-resistant MFH cells had potential to differentiate into osteogenic tissues by producing osteogenic factors, suggesting that MFH histology may be altered under anti-cancer drug treatments.
  • Recently, cancer differentiation-based therapy, that could be induced by anti-cancer drugs, has been implied.
  • MT-10R and MT-PR become useful experimental systems for studies on cellular differentiation provoked by anti-cancer drugs.
  • [MeSH-major] Bone Morphogenetic Proteins / biosynthesis. Cell Differentiation / drug effects. Cisplatin / pharmacology. Drug Resistance, Neoplasm / drug effects. Histiocytoma, Malignant Fibrous / pathology. Osteoblasts / pathology

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267196.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bmp6 protein, rat; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; 106441-73-0 / Osteopontin; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.19 / Bmp1 protein, rat; EC 3.4.24.19 / Bone Morphogenetic Protein 1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Iguchi Y, Takahashi H, Yao K, Nakayama M, Nagai H, Okamoto M: Malignant fibrous histiocytoma of the nasal cavity and paranasal sinuses: review of the last 30 years. Acta Otolaryngol Suppl; 2002;(547):75-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the nasal cavity and paranasal sinuses: review of the last 30 years.
  • The clinical and pathologic features of four patients with malignant fibrous histiocytoma of the maxillary sinus were studied.
  • All patients were male, with an age range of 43-71 years at the time of diagnosis.
  • Pathologically, three patients were subclassified with the striform-pleomorphic type of malignant fibrous histiocytoma and one with the myxoid type.
  • All patients were operated on and received various combinations of pre- and postoperative irradiation and intra-arterial chemotherapy given via the temporal artery.
  • Two patients developed local recurrences and died.
  • None of the patients developed locoregional lymph node or systemic metastases.
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / therapy. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Male. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / radiography. Nasal Cavity / surgery. Outcome Assessment (Health Care). Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212601.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 13
  •  go-up   go-down


78. Toda R, Yotsumoto G, Masuda H, Sakata R, Umekita Y: Surgical treatment of malignant fibrous histiocytoma in the left atrium and pulmonary veins: report of a case. Surg Today; 2002;32(3):270-3
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of malignant fibrous histiocytoma in the left atrium and pulmonary veins: report of a case.
  • This report describes the case of a 16-year-old boy who underwent surgical treatment of a cardiac malignant fibrous histiocytoma (MFH).
  • No adjuvant chemotherapy or radiotherapy was given.
  • While there has been no evidence of local recurrence or metastasis in the 9 months since his operation, strict follow-up is being done by UCG and computed tomography.
  • Therefore, we reviewed only the surgical cases of this type of cardiac tumor documented in the literature.
  • [MeSH-major] Heart Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery. Pulmonary Veins. Vascular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11991516.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 39
  •  go-up   go-down


79. Saga K, Sato T, Abiko M, Takahashi N, Ikeda E: [A case of primary malignant fibrous histiocytoma of the lung]. Kyobu Geka; 2001 Mar;54(3):191-4
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary malignant fibrous histiocytoma of the lung].
  • A 68-year-old woman presented with a complaint of coughing and chestroentgenography and computed tomography revealed a very large, irregular mass in the left inferior lobe of the lung.
  • The patient received preoperative chemotherapy including cisplatin with vindesine as employed for non-small cell lung cancer.
  • She demonstrated a clinical response after three cycles of the chemotherapy and underwent surgery successfully.
  • A postoperative diagnosis of MFH was made based on the histology of the tumor, which was pleomorphic with a storiform pattern.
  • The patient underwent a further three cycles of postoperative chemotherapy and has remained disease-free for 12 months after tumor resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Benign Fibrous / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11244748.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


80. Wang BG, Liang H, Cui QH, Wang JC, Liu JZ: [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases]. Zhonghua Zhong Liu Za Zhi; 2004 Jun;26(6):373-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases].
  • OBJECTIVE: To investigate the diagnosis and treatment of malignant fibrous histiocytoma of the retroperitoneum (MFHR).
  • METHODS: The clinicopathological features, treatment and prognosis of 31 patients with MFHR were retrospectively analyzed.
  • The histopathologic types of the tumor were inflammatory, storiform-pleomorphic, myxoid and giant cell in 16, 10, 4 and 1 cases.
  • The overall survival rate of 1-, 3- and 5-year was 61.3% +/- 9.8%, 31.6% +/- 11.3% and 21.1% +/- 11.4% with a median survival time of 17.0 +/- 6.3 months.
  • Postoperative radiotherapy of 20 - 45 Gy was able to prolong the median survival from 12.1 +/- 11.6 months of surgery alone to 26.4 +/- 22.0 months of surgery plus postoperative radiotherapy though without statistical significance (P = 0.051).
  • Postoperative CHOP chemotherapy was not shown to be beneficial.
  • CONCLUSION: Chemotherapy remains the important method of cure.
  • The survival in patients with MFHR might be improved by complete resection combined with chemotherapy or/and radiotherapy.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatectomy. Postoperative Period. Prednisone / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Splenectomy. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15312351.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


81. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Rea S, Nappi G: Cardiac metastases in malignant fibrous histiocytoma. A case report. Tumori; 2006 Jan-Feb;92(1):76-8
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastases in malignant fibrous histiocytoma. A case report.
  • Malignant fibrous histiocytoma metastasizing to the left ventricle is an uncommon form of cardiac malignancy.
  • This report describes a rare case of left ventricular metastases from a malignant fibrous histiocytoma of the posterior compartment of the right thigh, recurring five years after treatment with surgery, hyperthermic perfusion of the limb and radiotherapy.
  • A partial response was obtained with standard and high-dose chemotherapy with peripheral blood progenitor cell transplantation.
  • [MeSH-major] Heart Neoplasms / secondary. Histiocytoma, Malignant Fibrous / secondary. Histiocytoma, Malignant Fibrous / therapy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Ventricles. Hematopoietic Stem Cell Transplantation. Humans. Male. Thigh. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683388.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Shioiri M, Seike K, Kametaka H, Makino H, Miura S, Okubo Y, Fujisaki K, Koyama T: [A case of primary retroperitoneal malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2357-8
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary retroperitoneal malignant fibrous histiocytoma].
  • Based on histological and immunohistochemical inspection, the tumor was diagnosed as malignant fibrous histocytoma (MFH) on retroperitoneum.
  • No treatment was undergone as the postoperative course was good, however, computed tomography (CT) for 8 months after the surgery showed the sign of local recurrence.
  • It has been reported that the prognosis of MFH was very poor and a surgical resection was the only treatment for MFH, or we are expecting to find an effective treatment quickly such as a new combined chemotherapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037421.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Shinozaki T, Kato K, Watanabe H, Yanagawa T, Ahmed AR, Takagishi K: Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue. J Orthop Sci; 2001;6(4):339-42
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminant analysis of prognostic factors for malignant fibrous histiocytoma in soft tissue.
  • We prospectively followed 32 patients with soft-tissue malignant fibrous histiocytoma (MFH).
  • Parameters were age; sex; tumor size, location, and depth; operative method; chemotherapy; radiotherapy; and histology.
  • Male patients with deep-seated storiform-pleomorphic type MFH, receiving less comprehensive surgery, had the greatest risk of local recurrence or early metastases.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11479763.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


84. Yoshida N, Miyanari N, Yamamoto Y, Egami H: Successful treatment of malignant fibrous histiocytoma originating in the chest wall: report of a case. Surg Today; 2006;36(8):714-21
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of malignant fibrous histiocytoma originating in the chest wall: report of a case.
  • Malignant fibrous histiocytoma (MFH) rarely originates in the chest wall, so its clinical features are not well defined.
  • We reviewed the clinical features and treatment strategies of the total 39 cases of MFH originating in the chest wall reported from Japan.
  • The fact that all patients who underwent wide excision with negative margins at the primary operation were alive without recurrence at the time of each report, despite a local recurrence rate as high as 40%, shows the importance of this operative strategy.
  • Neoadjuvant chemotherapy plus radiation therapy may be worthwhile for patients with advanced disease.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Thoracic Neoplasms / surgery. Thoracic Wall

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):141-52 [9669607.001]
  • [Cites] J Thorac Cardiovasc Surg. 1982 Sep;84(3):367-72 [6287120.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1984 Jan;22(1):68-73 [6330412.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Aug;108(2):395-6 [8041197.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1985 Jun;23 (6):746-50 [2999490.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):167-78 [6243239.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):610-5 [3942997.001]
  • [Cites] Cancer. 1977 Nov;40(5):2010-4 [200332.001]
  • [Cites] Kyobu Geka. 1996 Jan;49(1):21-5 [8558801.001]
  • [Cites] Rinsho Kyobu Geka. 1987;7(5):487-90 [9301805.001]
  • [Cites] Cancer Invest. 2001;19(1):23-7 [11291552.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1990 Jan;38(1):171-7 [2158518.001]
  • [Cites] Kyobu Geka. 2003 Aug;56(9):742-6 [12931582.001]
  • [Cites] Ann Thorac Surg. 1986 Jun;41(6):597-601 [3013106.001]
  • [Cites] Fukuoka Igaku Zasshi. 1979 Oct;70(10):585-613 [230139.001]
  • [Cites] Acta Pathol Jpn. 1980 Sep;30(5):727-41 [6255736.001]
  • [Cites] Nihon Seikeigeka Gakkai Zasshi. 1983 Jan;57(1):101-10 [6306122.001]
  • [Cites] Surg Today. 1998;28(4):459-63 [9590721.001]
  • [Cites] Surg Today. 2002;32(1):69-71 [11871822.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):370-3 [3802023.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1993 Feb;41(2):310-4 [8386210.001]
  • [Cites] Kyobu Geka. 2000 Jul;53(7):600-4 [10897576.001]
  • [Cites] Kyobu Geka. 1997 Aug;50(9):800-3 [9259146.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1988 Oct;89(10):1722-5 [2849040.001]
  • [Cites] Cancer. 1985 Jun 15;55(12 ):2804-11 [2986825.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1419-23 [6244081.001]
  • [Cites] Nihon Ronen Igakkai Zasshi. 1995 Aug-Sep;32(8-9):592-6 [8531406.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):371-4 [11888478.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1994 Jul;42(7):1117-22 [8089587.001]
  • (PMID = 16865516.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 50
  •  go-up   go-down


85. Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y: Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. In Vivo; 2003 May-Jun;17(3):255-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
  • We have recently established rat osteosarcoma and malignant fibrous histiocytoma (MFH) cell lines.
  • The level of c-kit mRNA expression were almost negligible hardly in all cell lines.
  • The effect of STI571 on cellular growth measured by MTS colorimetric dye reduction showed that the growth of each cell line was inhibited in a dose- and time-dependent manner.
  • These data suggested that STI571 tyrosine kinase inhibitor plays a role in blocking or slowing the rate of growth of MFH and osteosarcoma cells expressing tyrosine kinase type receptor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Osteosarcoma / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Animals. Benzamides. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Imatinib Mesylate. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / genetics. Rats

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12929576.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


86. Marchese R, Bufo P, Carrieri G, Bove G: Malignant fibrous histiocytoma of the kidney treated with nephrectomy and adjuvant radiotherapy: a case report. Case Rep Med; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the kidney treated with nephrectomy and adjuvant radiotherapy: a case report.
  • Malignant fibrous histiocytoma (MFH) usually presents in the extremities or retroperitoneum.
  • Although radical nephrectomy is the most beneficial curative choice for this neoplasm, patients are often treated with adjuvant chemotherapy due to high risk of local recurrence and distant metastases.
  • We describe a case of a 68-year-old woman affected by MFH, treated with both nephrectomy and radiotherapy without systemic therapy showing an unexpected twenty-four-month postsurgery survival outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936124.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2948928
  •  go-up   go-down


87. Sugihara T, Fujimura T, Kume H, Homma Y: Successful treatment of metastatic malignant fibrous histiocytoma of the kidney. Urol Int; 2010;85(1):118-20
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic malignant fibrous histiocytoma of the kidney.
  • Malignant fibrous histiocytoma (MFH) of the kidney is a rare sarcoma that often undergoes local recurrence and/or distant metastasis.
  • However, little is known about the outcome of metastatic diseases.
  • We present the case of a 46-year-old male suffering from renal MFH with pulmonary metastasis, who has undergone complete response for 3 years after surgical resection and MAID chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Histiocytoma, Malignant Fibrous / therapy. Kidney Neoplasms / therapy. Lung Neoplasms / therapy. Nephrectomy. Thoracoscopy
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20516674.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


88. Povo-Martín I, Gallego-Vilar D, Bosquet-Sanz M, Miralles-Aguado J, Gimeno-Argente V, Rodrigo-Aliaga M, Gallego-Gómez J: [Malignant fibrous histiocytoma of the bladder. A literature review]. Actas Urol Esp; 2010 Apr;34(4):378-85
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of the bladder. A literature review].
  • [Transliterated title] Histiocitoma fibroso maligno de vejiga. Revisión bibliográfica.
  • OBJECTIVES: Malignant fibrous histiocytoma (MFH) is an uncommon urinary tract tumor.
  • This paper is intended to provide an update on its diagnostic criteria, pathological and immunohistochemical characteristics, histological classification, prognostic factors, and alternative treatments.
  • Stage T3 MFH was found in 72% of cases at the time of diagnosis.
  • MFH local recurrence and distant metastasis rates were 50% and 25% respectively after surgical treatment only.
  • CONCLUSIONS: MFH of the bladder is a tumor with high local and distant recurrence rates and a low survival rate, and therefore requires early and aggressive treatment.
  • Radical cystectomy with lymphadenectomy and adjuvant radiotherapy is considered to be the treatment of choice, eventually associated to chemotherapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20470701.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


89. Fu DL, Yang F, Maskay A, Long J, Jin C, Yu XJ, Xu J, Zhou ZW, Ni QX: Primary intestinal malignant fibrous histiocytoma: two case reports. World J Gastroenterol; 2007 Feb 28;13(8):1299-302
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal malignant fibrous histiocytoma: two case reports.
  • Malignant fibrous histiocytoma (MFH) occurs most commonly in the extremities and trunk, but rarely in the intestine.
  • At laparotomy, a tumor was found originating from the cecum, with a suspicious metastatic nodule on the surface of the right lobe of the liver.
  • They were not treated with chemotherapy or radiotherapy and both died within 3 mo.
  • Complete surgical excision is preferred, adjuvant chemotherapy or radiotherapy may be advisable.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Intestinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 May;26(3):305-10 [10741601.001]
  • [Cites] Surg Today. 2005;35(4):323-7 [15815852.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Skeletal Radiol. 2003 Nov;32(11):613-8 [14517697.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1156-60 [15387338.001]
  • [Cites] Burns. 2004 Nov;30(7):742-5 [15475153.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):554-63 [7690726.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):91-6 [8548744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):718-24 [9361108.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):134-42 [9428357.001]
  • [Cites] Surg Today. 1999;29(2):160-4 [10030742.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):447-8 [10419723.001]
  • [Cites] APMIS. 1999 Sep;107(9):837-42 [10519319.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Surg Today. 2001;31(3):242-5 [11318129.001]
  • (PMID = 17451221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147015
  •  go-up   go-down


90. Carnero S, Terán P, Trillo E: Malignant fibrous histiocytoma arising in a gouty tophus at the second metacarpophalangeal joint. J Plast Reconstr Aesthet Surg; 2006;59(7):775-8
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma arising in a gouty tophus at the second metacarpophalangeal joint.
  • We report a case of concomitant malignant fibrous histiocytoma (MFH) and tophaceous deposit at the second metacarpophalangeal joint in a 76-year-old man.
  • The patient underwent surgical treatment, local radiotherapy and adjuvant chemotherapy and was disease free at the time of his last examination.
  • [MeSH-major] Arthritis, Gouty / complications. Histiocytoma, Malignant Fibrous / complications. Metacarpophalangeal Joint
  • [MeSH-minor] Aged. Combined Modality Therapy. Gout / complications. Humans. Immunohistochemistry / methods. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782578.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M, Yamamoto T: Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. Anticancer Res; 2004 Sep-Oct;24(5A):2675-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
  • BACKGROUND: Malignant fibrous histiocytoma (MFH) is one of the most common high-grade sarcomas in bone and soft tissue and, due to its chemo-resistance, the prognosis of the disease is poor.
  • ST1571 is a tyrosine kinase inhibitor that was initially developed as a BCR/ABL inhibitor for chronic myeloid leukemia patients.
  • STI571 inhibited cell proliferation of TNMY1, GBS-1 and Nara-F in a dose- and time-dependent manner, but cell proliferation of Nara-H was not inhibited by ST1571 at concentrations of 10 microM or less.
  • [MeSH-major] Histiocytoma, Benign Fibrous / drug therapy. Piperazines / pharmacology. Protease Inhibitors / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Benzamides. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Imatinib Mesylate. Proto-Oncogene Proteins c-kit / biosynthesis. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / genetics

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517872.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protease Inhibitors; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


92. Chibon F, Mariani O, Derré J, Mairal A, Coindre JM, Guillou L, Sastre X, Pédeutour F, Aurias A: ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer; 2004 May;40(1):32-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications.
  • Malignant fibrous histiocytomas (MFHs) are aggressive tumors without any definable line of differentiation.
  • Treatment of a cell line with specific inhibitors of ASK1 protein resulted in the bypass of the differentiation block and induction of a strong adipocytic differentiation.
  • These observations indicate that ASK1 is a target for new therapeutic management of these aggressive tumors.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 6 / genetics. Gene Amplification / genetics. Histiocytoma, Benign Fibrous / drug therapy. MAP Kinase Kinase Kinases / antagonists & inhibitors. MAP Kinase Kinase Kinases / physiology. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Adipocytes / drug effects. Adipocytes / pathology. Aged. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / enzymology. Liposarcoma / genetics. MAP Kinase Kinase Kinase 5. MAP Kinase Signaling System / drug effects. MAP Kinase Signaling System / genetics. Male. Middle Aged. Nucleic Acid Hybridization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15034865.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.11.25 / MAP Kinase Kinase Kinase 5; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP3K5 protein, human
  •  go-up   go-down


93. Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A, Memon M, Younge D, Moreau P, Gray A, Schultz H: Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol; 2002 Feb;25(1):16-22
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma: a retrospective study of 109 cases.
  • The purpose of this report is to assess the prognostic factors that could influence management and clinical outcome of malignant fibrous histiocytoma (MFH) of soft tissues.
  • Between 1975 and 1998, 109 patients diagnosed with MFH of the soft tissues, seen at King Faisal Specialist Hospital and Research Center, have been reviewed.
  • The remaining 92 patients had localized disease and had surgery as the primary treatment modality with or without radiotherapy and/or chemotherapy.
  • Complete surgical resection at the time of primary tumor presentation is likely to afford the best chance for RFS and OS.
  • Radiation therapy plays an important role, in combination with surgery for better local control, particularly in high-grade lesions, and in cases with positive surgical margins after wide complete gross excision.
  • The role of adjuvant chemotherapy remains investigational.
  • [MeSH-major] Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11823689.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M: Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. Anticancer Res; 2007 Jan-Feb;27(1A):423-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
  • BACKGROUND: Malignant fibrous histiocytoma (MFH) is one of the most diffuse and aggressive tumors among soft tissue sarcomas in adults, but still poorly characterized from the molecular viewpoint.
  • Imatinib mesylate inhibited PDGFRs and c-Kit phosphorylation in TNMY1 cells affecting the tumorigenicity, in the control group (139 mm3 SD +/- 1.03) and treatment group (126.2 mm3 SD +/- 1.63) but did not affect the tumorigenicity of Nara H cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Histiocytoma, Malignant Fibrous / drug therapy. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Animals. Benzamides. Cell Growth Processes / drug effects. Cell Line, Tumor. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Mice. Mice, Nude. Phosphorylation / drug effects. Proto-Oncogene Proteins c-kit / biosynthesis. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / genetics. Receptor, Platelet-Derived Growth Factor beta / metabolism. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352263.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


95. Zlowodzki M, Allen B, Schreibman KL, Vance RB, Kregor PJ: CASE REPORTS: malignant fibrous histiocytoma of bone arising in chronic osteomyelitis. Clin Orthop Relat Res; 2005 Oct;439:269-73
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CASE REPORTS: malignant fibrous histiocytoma of bone arising in chronic osteomyelitis.
  • According to published reports, a coincidence of malignant fibrous histiocytoma of bone and post-fracture osteomyelitis has occurred in only four patients.
  • Our report details the treatment of 51-year-old man with a fracture 15 years previously and subsequent chronic osteomyelitis of the left distal femur.
  • The original treatment was open reduction and casting.
  • Fifteen years after the injury, the patient presented to the emergency room with increasing pain, erythema, swelling, and increased purulent discharge from the distal femur.
  • The left distal femur was radically resected for treatment of osteomyelitis.
  • Histologic samples of the specimen revealed malignant fibrous histiocytoma of bone.
  • One of two inguinal lymph nodes removed at that time was positive for malignant fibrous histiocytoma.
  • The patient had additional chemotherapy.
  • [MeSH-major] Bone Neoplasms / complications. Histiocytoma, Malignant Fibrous / complications. Osteomyelitis / complications
  • [MeSH-minor] Chronic Disease. Femur / pathology. Femur / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205169.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Chuman H: [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2003 May;30(5):626-33
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma].
  • Malignant fibrous histiocytoma (MFH) is a tumor about which much remains unknown.
  • The cell origin, molecular mechanism of pleomophism and mechanism of pleomorphic change in a cell undergoing malignant change have not been elucidated.
  • MFH has been regarded as one tumor classification from its special histopathological features.
  • In clinical pathological studies these tumors are divided into low-grade fibrous tumors and fibrous histiocytic tumors.
  • The sensitivity of MFH to radiotherapy and chemotherapy is insufficient, and evidence is lacking for adjuvant treatment.
  • Rescue following initial treatment failure is extremely difficult.
  • For treatment of bone and soft tissue sarcoma, a correct diagnosis and initial treatment are extremely important.
  • Many cases need to be accumulated in joint clinical studies across fields according to organ and specialty, and effective treatment method developed.
  • We need to advance the standardization of treatment for MFH, and eliminate wrong initial treatment through the active provision of information.
  • [MeSH-major] Bone Neoplasms. Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Prognosis. Radiotherapy, Adjuvant. Sarcoma / pathology. Sarcoma / surgery. Sarcoma / therapy. Survival Rate

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Efe T, Heyse TJ, Schofer MD, Fuchs-Winkelmann S, Rexin P, Schmitt J: Malignant fibrous histiocytoma of the distal femur after an arthroscopic anterior cruciate ligament reconstruction: A case report and a review of the literature. BMC Cancer; 2010;10:264
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the distal femur after an arthroscopic anterior cruciate ligament reconstruction: A case report and a review of the literature.
  • To our knowledge, no case of osseous malignant fibrous histiocytoma after anterior cruciate ligament reconstruction is reported in the literature.
  • Biopsy determined a malignant fibrous histiocytoma.
  • After neoadjuvant chemotherapy, wide tumor resection and distal femur reconstruction with a silver-coated non-cemented tumor knee joint prosthesis was performed.
  • Adjuvant chemotherapy was continued according to the EURAMOS 1 protocol.
  • CONCLUSIONS: Though secondary malignant degeneration after orthopaedic implants or prostheses is not very likely, the attending physician should take this into consideration, especially if symptoms worsen severely over a short period of time.
  • [MeSH-major] Anterior Cruciate Ligament / surgery. Arthroscopy / adverse effects. Femoral Neoplasms / etiology. Histiocytoma, Malignant Fibrous / etiology. Tendon Transfer / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arthroplasty, Replacement, Knee. Biopsy. Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Neoadjuvant Therapy. Pain / etiology. Reoperation. Rupture. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1979 Jan;10(1):57-70 [218883.001]
  • [Cites] Radiology. 1972 Sep;104(3):497-508 [4340636.001]
  • [Cites] Schweiz Med Wochenschr. 1980 Dec 27;110(52):2021-4 [6269177.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] Am J Surg Pathol. 1985 Dec;9(12):853-71 [3000204.001]
  • [Cites] Chemioterapia. 1988 Dec;7(6):406-13 [2851393.001]
  • [Cites] Orthop Rev. 1994 May;23(5):427-32 [8041576.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] J Bone Joint Surg Am. 2005 Feb;87(2):404-9 [15687167.001]
  • [Cites] Knee. 2006 Jun;13(3):184-8 [16603363.001]
  • [Cites] Clin Orthop Relat Res. 2006 Sep;450:76-81 [16906097.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):504-7 [18038887.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jul;467(7):1820-5 [19229663.001]
  • [Cites] Burns. 1999 Dec;25(8):764-7 [10630863.001]
  • [Cites] Arthroscopy. 2001 May;17(5):461-76 [11337712.001]
  • [Cites] Orthopade. 2002 Aug;31(8):731-40 [12426751.001]
  • [Cites] Clin Orthop Relat Res. 2004 Feb;(419):214-7 [15021157.001]
  • [Cites] Dtsch Med Wochenschr. 1981 Mar 13;106(11):336-9 [6258891.001]
  • (PMID = 20529315.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2889898
  •  go-up   go-down


98. Lan Ma H, Metze D, Luger TA, Steinhoff M: Successful treatment of generalized eruptive histiocytoma with PUVA. J Dtsch Dermatol Ges; 2007 Feb;5(2):131-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of generalized eruptive histiocytoma with PUVA.
  • Generalized eruptive histiocytoma (GEH) is a rare benign skin disease mainly affecting adults which belongs to the family of non-Langerhans-cell histiocytoses.
  • A 32-year-old Caucasian woman developed disseminated, monomorphic papules of the trunk after a common cold with sinusitis.
  • No neoplastic diseases were found during thorough examinations.
  • Systemic PUVA therapy produced rapid regression of the skin lesions.
  • After 10 treatments the lesions began to regress leaving slight papules and multiple brown hyperpigmentations.
  • The lesions resolved completely after 20 PUVA treatments.
  • Systemic PUVA therapy represents a promising option for the treatment of GEH.
  • [MeSH-major] Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytosis, Langerhans-Cell / drug therapy. Histiocytosis, Langerhans-Cell / pathology. PUVA Therapy / methods. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274780.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Schlott T, Taubert H, Fayyazi A, Schweyer S, Bartel F, Korabiowska M, Brinck U: Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide. Anticancer Res; 2004 Nov-Dec;24(6):3819-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide.
  • Soft tissue sarcomas frequently carry p53 mutations reducing chemotherapeutical response.
  • Especially malignant fibrous histiocytoma (MFH) reveals a reduced ifosfamide (IF) chemosensitivity when compared to other sarcoma entities.
  • The aim was to identify candidate genes possibly involved in the anti-apoptotic response of p53-deficient MFH cells during chemotherapy.
  • PCR, real-time RT-PCR and confocal laser scanning microscopy were applied on primary cultures of MFH cells containing defective p53 genes.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / genetics. Ifosfamide / pharmacology. Tumor Suppressor Protein p53 / deficiency
  • [MeSH-minor] Actins / biosynthesis. Actins / genetics. Alternative Splicing / drug effects. Caspase 3. Caspases / metabolism. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinases / biosynthesis. Cyclin-Dependent Kinases / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Genes, Tumor Suppressor. Humans. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-mdm2. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retinoblastoma Protein / biosynthesis. Retinoblastoma Protein / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736417.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Antineoplastic Agents, Alkylating; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


100. Shoja MM, Tubbs RS, Asvadi I, Farahani RM, Seyednejad F, Oakes WJ: Malignant fibrous histiocytoma of the spermatic cord: a case report and review of the literature. Folia Morphol (Warsz); 2006 Nov;65(4):390-5
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the spermatic cord: a case report and review of the literature.
  • Malignant fibrous histiocytoma (MFH) is a morphologically ill-defined tumour of the soft tissues and may involve nearly every organ of the body.
  • We report a 69-year-old man found to have a left spermatic cord MFH and retroperitoneal and mediastinal lymphadenopathy, who was treated with radical orchiectomy and adjuvant chemotherapy.
  • The morphological findings of the spermatic tumour are presented and the literature is reviewed to clarify the potential diagnostic/therapeutic approaches and the prognosis related to spermatic cord MFH.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Histiocytoma, Malignant Fibrous / pathology. Spermatic Cord / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Male. Orchiectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171621.001).
  • [ISSN] 0015-5659
  • [Journal-full-title] Folia morphologica
  • [ISO-abbreviation] Folia Morphol. (Warsz)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 52
  •  go-up   go-down






Advertisement